



(51) International Patent Classification:

C07D 487/04 (2006.01) **A61P 25/28** (2006.01)
A61K 31/522 (2006.01)

(21) International Application Number:

PCT/EP2010/061735

(22) International Filing Date:

12 August 2010 (12.08.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09167716.1 12 August 2009 (12.08.2009) EP

(71) Applicant (for all designated States except US):

BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Straße 173, 55216 Ingelheim am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only):

HEINE, Niklas [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **DORNER-CIOSSEK, Cornelia** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **EICKMEIER, Christian** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **FIEGEN, Dennis** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **FOX, Thomas** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **FUCHS, Klaus** [DE/DE]; Boehringer Ingel-

heim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **GIOVANNINI, Riccardo** [IT/IT]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **ROSENBROCK, Holger** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **SCHAENZLE, Gerhard** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **BAERFACKER, Lars** [DE/DE]; Walter-Flex-Strasse 29, 46047 Oberhausen (DE).

(74) Agents: **HAMMAN, Heinz** et al.; Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS



(57) Abstract: The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.



Declarations under Rule 4.17:

Published:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))* — *with international search report (Art. 21(3))*

New Compounds for the Treatment of CNS Disorders

The invention relates to novel pyrazolopyrimidinones. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

BACKGROUND OF THE INVENTION

The inhibition of phosphodiesterase 9A (PDE9A) is one of the current concepts to find new access paths to the treatment of cognitive impairments due to CNS disorders like Alzheimer's Disease or due to any other neurodegenerative process of the brain. With the present invention, new compounds are presented that follow this concept.

Phosphodiesterase 9A is one member of the wide family of phosphodiesterases. These kinds of enzymes modulate the levels of the cyclic nucleotides 5'-3' cyclic adenosine monophosphate (cAMP) and 5'-3' cyclic guanosine monophosphate (cGMP). These cyclic nucleotides (cAMP and cGMP) are important second messengers and therefore play a central role in cellular signal transduction cascades. Each of them reactivates inter alia, but not exclusively, protein kinases. The protein kinase activated by cAMP is called protein kinase A (PKA), and the protein kinase activated by cGMP is called protein kinase G (PKG). Activated PKA and PKG are able in turn to phosphorylate a number of cellular effector proteins (e.g. ion channels, G-protein-coupled receptors, structural proteins, transcription factors). It is possible in this way for the second messengers cAMP and cGMP to control a wide variety of physiological processes in a wide variety of organs. However, the cyclic nucleotides are also able to act directly on effector molecules. Thus, it is known, for example, that

- 2 -

cGMP is able to act directly on ion channels and thus is able to influence the cellular ion concentration (review in: Wei *et al.*, *Prog. Neurobiol.*, **1998**, 56, 37-64). The phosphodiesterases (PDE) are a control mechanism for controlling the activity of cAMP and cGMP and thus in turn for the corresponding physiological processes.

5 PDEs hydrolyse the cyclic monophosphates to the inactive monophosphates AMP and GMP. Currently, 11 PDE families have been defined on the basis of the sequence homology of the corresponding genes. Individual PDE genes within a family are differentiated by letters (e.g. PDE1A and PDE1B). If different splice variants within a gene also occur, this is then indicated by an additional numbering
10 after the letters (e.g. PDE1A1).

Human PDE9A was cloned and sequenced in 1998. The amino acid identity with other PDEs does not exceed 34% (PDE8A) and is never less than 28% (PDE5A). With a Michaelis-Menten constant (Km) of 170 nanomolar, PDE9A has high affinity
15 for cGMP. In addition, PDE9A is selective for cGMP (Km for cAMP=230 micromolar). PDE9A has no cGMP binding domain, suggesting that the enzyme activity is not regulated by cGMP. It was shown in a Western blot analysis that PDE9A is expressed in humans inter alia in testes, brain, small intestine, skeletal muscle, heart, lung, thymus and spleen. The highest expression was found in the brain, small
20 intestine, kidney, prostate, colon, and spleen (Fisher *et al.*, *J. Biol. Chem.*, **1998**, 273 (25), 15559-15564; Wang *et al.*, *Gene*, **2003**, 314, 15-27). The gene for human PDE9A is located on chromosome 21q22.3 and comprises 21 exons. 4 alternative splice variants of PDE9A have been identified (Guipponi *et al.*, *Hum. Genet.*, **1998**, 103, 386-392). Classical PDE inhibitors do not inhibit human PDE9A. Thus, IBMX,
25 dipyridamole, SKF94120, rolipram and vinpocetine show no inhibition on the isolated enzyme in concentrations of up to 100 micromolar. An IC₅₀ of 35 micromolar has been demonstrated for zaprinast (Fisher *et al.*, *J. Biol. Chem.*, **1998**, 273 (25), 15559-15564).

30 Murine PDE9A was cloned and sequenced in 1998 by Soderling *et al.* (*J. Biol. Chem.*, **1998**, 273 (19), 15553-15558). This has, like the human form, high affinity for cGMP with a Km of 70 nanomolar. Particularly high expression was found in the

- 3 -

mouse kidney, brain, lung and liver. Murine PDE9A is not inhibited by IBMX in concentrations below 200 micromolar either; the IC₅₀ for zaprinast is 29 micromolar (Soderling *et al.*, *J. Biol. Chem.*, **1998**, 273 (19), 15553-15558). It has been found that PDE9A is strongly expressed in some regions of the rat brain. These include olfactory bulb, hippocampus, cortex, basal ganglia and basal forebrain (Andreeva *et al.*, *J. Neurosci.*, **2001**, 21 (22), 9068-9076). The hippocampus, cortex and basal forebrain in particular play an important role in learning and memory processes. As already mentioned above, PDE9A is distinguished by having particularly high affinity for cGMP. PDE9A is therefore active even at low physiological concentrations, in contrast to PDE2A (K_m=10 micromolar; Martins *et al.*, *J. Biol. Chem.*, **1982**, 257, 1973-1979), PDE5A (K_m=4 micromolar; Francis *et al.*, *J. Biol. Chem.*, **1980**, 255, 620-626), PDE6A (K_m=17 micromolar; Gillespie and Beavo, *J. Biol. Chem.*, **1988**, 263 (17), 8133-8141) and PDE11A (K_m=0.52 micromolar; Fawcett *et al.*, *Proc. Nat. Acad. Sci.*, **2000**, 97 (7), 3702-3707). In contrast to PDE2A (Murashima *et al.*, *Biochemistry*, **1990**, 29, 5285-5292), the catalytic activity of PDE9A is not increased by cGMP because it has no GAF domain (cGMP-binding domain via which the PDE activity is allosterically increased) (Beavo *et al.*, *Current Opinion in Cell Biology*, **2000**, 12, 174-179). PDE9A inhibitors may therefore lead to an increase in the baseline cGMP concentration.

This outline will make it evident that PDE9A engages into specific physiological processes in a characteristic and unique manner, which distinguishes the role of PDE9A characteristically from any of the other PDE family members.

WO04099210 discloses 6-arylmethyl-substituted pyrazolopyrimidinones which are PDE9 inhibitors. The compounds do not have a non-aromatic heterocyclic moiety in the 1 position of the pyrazolopyrimidine.

WO04099211 discloses 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines and their use for the improvement of cognition, concentration etc..

DE 102 38 722 discloses the use of PDE9A-inhibitors for the improvement of cognition, concentration etc..

- 4 -

WO04018474 discloses phenyl-substituted pyrazolopyrimidines and their use for the improvement of perception, concentration learning and/or memory.

WO04026876 discloses alkyl-substituted pyrazolopyrimidines which and their use for the improvement of awareness, concentration learning capacity and/or memory performance.

WO04096811 discloses heterocyclic bicycles as PDE9 inhibitors for the treatment of diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.

Other prior art is directed to chemically similar nucleoside derivatives. As examples it is referred to WO02057425, which discloses nucleoside derivatives, which are inhibitors of RNA-dependent RNA viral polymerase, or WO01060315, which discloses nucleoside derivatives for the treatment of hepatitis C infection or EP679657, which discloses compounds that serve as ribonucleoside analogues or US2002058635, which discloses purine L-nucleoside compounds, in which both the purine rings and the pentose ring are either modified, functionalized, or both. So the pentose ring for example must show at least one esterified hydroxy group.

WO06084281 discloses inhibitors of the E1 acitvation enzyme that have a sulfonamid moiety.

US3732225 describes pyrazolopyrimidinones which have an antiinflammatory and blood glucose-lowering effect.

DE2408906 describes styrylpyrazolopyrimidinones which can be employed as antimicrobial and anti-inflammatory agents for the treatment of, for example, oedema.

OBJECTIVE OF THE INVENTION

The above cited prior art makes it evident that changes in the substitution pattern of pyrazolopyrimidinones result in interesting changes concerning biological activity, respectively changes in the affinity towards different target enzymes.

- 5 -

Therefore it is an objective of the present invention to provide compounds that effectively modulate PDE9A for the purpose of the development of a medicament, in particular in view of diseases, the treatment of which is accessible via PDE9A modulation.

- 5 It is another objective of the present invention to provide compounds that are useful for the manufacture of a medicament for the treatment of CNS disorders.


Yet another objective of the present invention is to provide compounds which show a favourable side effect profile.

- 10 Another objective of the present invention is to provide compounds that have a favourable selectively profile in favour for PDE9A inhibition over other PDE family members and by this may provide advantage.

Yet another objective is to provide such a medicament not only for treatment but also for prevention or modification of the corresponding disease.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

- 15 The compounds of the present invention are characterised by general formula I:



wherein

- R^1 is selected independently for each R^1 from the group R^{1a} consisting of Hydrogen, fluorine, chlorine, bromine, $NC-$, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -

- 6 -

alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, heterocyclyl-CO-, R¹⁰-O-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-, R¹⁰O-CO-, (R⁹)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R⁹)₂N-CO-(R¹⁰)N-, (R⁹)₂N-CO-O-, R¹⁰-O-CO-(R¹⁰)N-, R¹⁰-SO₂-(R¹⁰)N-, and C₁₋₆-alkyl-SO₂-,

where the above-mentioned members HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₁₋₃-alkyl-, heterocyclyl-CO-, and C₁₋₆-alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine, bromine, OH-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, (R¹⁰)₂N-CO-, C₃₋₆-cycloalkyl-, C₃₋₆-cycloalkyl-C₁₋₄-alkyl-, and C₁₋₆-alkyl-, preferably from the group consisting of fluorine, chlorine, bromine, OH-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, (R¹⁰)₂N-CO-, C₃₋₆-cycloalkyl-, and C₃₋₆-cycloalkyl-C₁₋₄-alkyl-,

L is selected from the integers 0, 1, 2 and 3,

x is selected from the integers 0, 1, 2, 3 and 4,

y is selected from the integers 0, 1 and 2,

D is selected from the group D^{1a} consisting of heterocyclyl,

- 7 -

wherein the above-mentioned members of the group D^{1a} may optionally be substituted by one or more substituents selected independently of one another from the group R^2 and/or optionally substituted by one group R^3

or

D is selected from the group D^{2a} consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctatrienyl and cyclooctatetraenyl,

wherein the above-mentioned members of the group D^{2a} may optionally be substituted by one or more substituents selected independently of one another from the group R^4 ,

or

D is selected from the group D^{3a} consisting of C_{1-8} -alkyl wherein the above-mentioned C_{1-8} -alkyl-group D^{3a} may optionally be substituted by one or more substituents selected independently of one another from the group R^5 .

or

D is selected from the group D^{4a} consisting of aryl wherein the above-mentioned aryl group D^{4a} may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R^6 . Preferred are such compounds wherein D^{4a} is substituted by not more than one R^6 .

or

D is selected from the group D^{5a} consisting of heteroaryl wherein the above-mentioned members of the group D^{5a} may optionally be substituted by one or more substituents selected independently of one another from the group R^6 . Preferred are such compounds wherein D^{5a} is substituted by not more than one R^6 .

- 8 -

R^2 is selected from the group R^{2a} consisting of
 H-, fluorine, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, R^{10} -O- C_{2-3} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $R^{10}O$ -CO-, $(R^{10})_2N$ -CO-, R^{10} -CO- $(R^{10})N$ -, R^{10} -CO-, $(R^{10})_2N$ -CO- $(R^{10})N$ -, R^{10} -O-CO- $(R^{10})N$ -, R^{10} -SO₂- $(R^{10})N$ -, C_{1-6} -alkyl-SO₂-, and oxo,

where the above-mentioned members HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl- (preferably C_{2-6} -alkyl), C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, R^{10} -O- C_{2-3} -alkyl-, $(R^{10})_2N$ - C_{1-3} -alkyl-, and C_{1-6} -alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of

fluorine, chlorine, bromine, NC-, O₂N-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, HO- C_{1-6} -alkyl-, C_{1-6} -alkyl-O-, C_{1-6} -alkyl-O- C_{1-6} -alkyl-, C_{1-6} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, and $(R^{10})_2N$ -CO-,

and in cases in that D^1 is a heterocyclyl group with NR^2 as ring member, R^2 shall be

independently of any other R^2 : H-, F_3C-CH_2 -, HF_2C-CH_2 -, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, R^{10} -O- C_{2-3} -alkyl-, $(R^{10})_2N$ - C_{1-3} -alkyl-, and C_{1-6} -alkyl-SO₂-

- 9 -

6-alkyl- , heteroaryl, heteroaryl- $C_{1-6}\text{-alkyl-}$, $R^{10}\text{-O-}C_{1-3}\text{-alkyl-}$, $R^{10}\text{O-CO-}$, $(R^{10})_2\text{N-CO-}$, $R^{10}\text{-CO-}$, $R^{10}\text{-SO}_2\text{-}$, and $C_{1-6}\text{-alkyl-SO}_2\text{-}$,

where the above-mentioned members $F_3C\text{-CH}_2\text{-}$, $HF_2C\text{-CH}_2\text{-}$, $C_{1-6}\text{-alkyl-}$, $C_{2-6}\text{-alkenyl-}$, $C_{2-6}\text{-alkynyl-}$, $C_{1-6}\text{-alkyl-S-}C_{1-3}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{1-6}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{2-6}\text{-alkenyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{2-6}\text{-alkynyl-}$, $C_{3-7}\text{-heterocyclyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{1-6}\text{-alkyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{2-6}\text{-alkenyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{2-6}\text{-alkynyl-}$, aryl, aryl- $C_{1-6}\text{-alkyl-}$, heteroaryl, heteroaryl- $C_{1-6}\text{-alkyl-}$, $R^{10}\text{-O-}C_{1-3}\text{-alkyl-}$, and $C_{1-6}\text{-alkyl-SO}_2\text{-}$ may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of

fluorine, $HO\text{-}$, $NC\text{-}$, $O_2N\text{-}$, $F_3C\text{-}$, $HF_2C\text{-}$, $FH_2C\text{-}$, $F_3C\text{-CH}_2\text{-}$, $HO\text{-}C_{1-6}\text{-alkyl-}$, $R^{10}\text{-O-}C_{1-6}\text{-alkyl-}$, $C_{1-6}\text{-alkyl-}$, $R^{10}\text{-O-}$, $(R^{10})_2N\text{-}$, $(R^{10})_2N\text{-}C_{1-3}\text{-alkyl-}$, and $(R^{10})_2N\text{-CO-}$,

R^3 is selected from the group R^{3a} consisting of $H\text{-}$, $HO\text{-}$ and $R^{10}\text{-O-}$,

R^4 is selected from the group R^{4a} consisting of $H\text{-}$, fluorine, chlorine, bromine, $HO\text{-}$, $NC\text{-}$, $F_3C\text{-}$, $HF_2C\text{-}$, $FH_2C\text{-}$, $F_3C\text{-CH}_2\text{-}$, carboxy-, $C_{1-6}\text{-alkyl-}$, $C_{2-6}\text{-alkenyl-}$, $C_{2-6}\text{-alkynyl-}$, $C_{1-6}\text{-alkyl-S-}$, $C_{1-6}\text{-alkyl-S-}C_{1-3}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{1-6}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{2-6}\text{-alkenyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{2-6}\text{-alkynyl-}$, $C_{3-7}\text{-heterocyclyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{1-6}\text{-alkyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{2-6}\text{-alkenyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{2-6}\text{-alkynyl-}$, aryl, aryl- $C_{1-6}\text{-alkyl-}$, aryl- $C_{2-6}\text{-alkenyl-}$, aryl- $C_{2-6}\text{-alkynyl-}$, heteroaryl-, heteroaryl- $C_{1-6}\text{-alkyl-}$, heteroaryl- $C_{2-6}\text{-alkenyl-}$, heteroaryl- $C_{2-6}\text{-alkynyl-}$, $R^{10}\text{-O-}$, $R^{10}\text{-O-}C_{1-3}\text{-alkyl-}$, $(R^{10})_2N\text{-}$, $(R^{10})_2N\text{-}C_{1-3}\text{-alkyl-}$, $R^{10}\text{O-CO-}$, $(R^{10})_2N\text{-CO-}$, $R^{10}\text{-CO-}(R^{10})N\text{-}$, $R^{10}\text{-CO-}$, $(R^{10})_2N\text{-CO-}(R^{10})N\text{-}$, $R^{10}\text{-O-CO-}(R^{10})N\text{-}$, $R^{10}\text{-SO}_2\text{-}(R^{10})N\text{-}$, and $C_{1-6}\text{-alkyl-SO}_2\text{-}$,

where the above-mentioned members $HF_2C\text{-}$, $FH_2C\text{-}$, $F_3C\text{-CH}_2\text{-}$, $C_{1-6}\text{-alkyl-}$,

- 10 -

C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-C₁₋₃-alkyl-, and C₁₋₆-alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

or

two substituents R^{4a} together form a C₂₋₆-alkylene bridge, wherein one or two CH₂ groups of the C₂₋₆-alkylene bridge may be replaced independently of one another by O, S, SO, SO₂, N(R¹⁰) or N-C(O)-R¹⁰ in such a way that in each case two O or S atoms or an O and an S atom are not joined together directly.

R⁵

is selected from the group R^{5a} consisting of H-, fluorine, chlorine, bromine, HO-, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, carboxy-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R¹⁰)₂N-CO-(R¹⁰)N-, R¹⁰-O-CO-(R¹⁰)N-, R¹⁰-SO₂-(R¹⁰)N-, and C₁₋₆-alkyl-SO₂-,

where the above-mentioned members HF₂C-, FH₂C-, F₃C-CH₂-, carboxy-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋

- 11 -

7-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-C₁₋₃-alkyl-, and C₁₋₆-alkyl-SO₂-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

R⁶ is selected from the group R^{6a} consisting of H-, fluorine, chlorine, bromine, HO-, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, carboxy-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R¹⁰)₂N-CO-(R¹⁰)N-, R¹⁰-O-CO-(R¹⁰)N-, R¹⁰-SO₂-(R¹⁰)N-, and C₁₋₆-alkyl-SO₂-,

where the above-mentioned members HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-C₁₋₃-alkyl- and C₁₋₆-alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine,

- 12 -

chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

R⁹ is selected independently for each R⁹ from the group R^{9a} consisting of H-, F₃C-CH₂-, C₂₋₆-alkenyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, heteroaryl-C₁₋₃-alkyl- and C₁₋₆-alkyl-, and where the above-mentioned members F₃C-CH₂-, C₂₋₆-alkenyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, heteroaryl-C₁₋₃-alkyl- and C₁₋₆-alkyl-, may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine, bromine, HO-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-O- and C₁₋₆-alkyl-,

R¹⁰ is selected independently for each R¹⁰ from the group R^{10a} consisting of H- (but not in case is part of a group being selected from R¹⁰O-CO-, R¹⁰-SO₂- or R¹⁰-CO-), F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, and heteroaryl-C₁₋₃-alkyl-, and in case where two R¹⁰ groups both are bound to the same nitrogen atom they may together with said nitrogen atom form a 3 to 12 membered heterocyclyl ring, and wherein one of the -CH₂-groups of the heterocyclic ring formed may be replaced by -O-, -S-, -NH-, -N(C₃₋₆-cycloalkyl)-, -N(C₃₋₆-cycloalkyl-C₁₋₄-alkyl)- or -N(C₁₋₄-alkyl)- and where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-,

- 13 -


HO-C₁₋₆-alkyl-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl- and C₁₋₆-alkyl-O-,

and pharmaceutically acceptable salt forms or solvates thereof.

- In one embodiment of the invention independent from any other group of the compound of formula (I), **D** is not oxetanyl, which is bound via the carbon atom next to the oxygen of the oxetanyl, there is no substituent attached to said carbon atom via an integral -CH₂- group.

In a preferred embodiment of the present invention

- D** is selected from the group D^{1b} consisting of heterocyclyl, defined by any of formulas I.1 or I.2 or I.3:
formula I.1:



with

$n = 1, 2, 3;$

meaning that the ring is not aromatic while for $n = 1$, one bond within the ring system optionally may be a double bond and for $n = 2$ or 3 one bond or two bonds within the ring system optionally may be (a) double bond(s), For each occasion the double bond preferably is a C-C double bond.

Preferably the ring system is saturated,


X^1, X^2, X^3 , independently from each other being CH_2 , CHR^2 , CHR^3 , $C(R^2)_2$, CR^2R^3 , O, NH, NR^2 , or $S(O)_r$ with $r = 0, 1, 2$, whereby at least one of X^1 , X^2 , X^3 is O, NH, NR^2 or $S(O)_r$, whereby the substituents R^2 and R^3 are

- 14 -

selected independently of each other;

The * represents the point of attachment to the nitrogen atom of the pyrazolo ring of formula I;

formula I.2:




with

A being the ring system of formula I.1;

B being a 3, 4, 5 or 6 membered second ring systems that is anellated to A and that beside the two atoms and one bond it shares with A consists only of carbon atoms and that may be saturated, partially saturated or aromatic, the ring system of formula I.2 may optionally be substituted by one or more substituents selected independently of one another from the group R^2 and/or optionally substituted by one group R^3 and whereby the two ring atoms that are shared by the two ring systems A and B both may be C-atoms, both may be N-atoms or one may be a C- and the other one may be a N-atom. Preferred are two C-atoms, or one C- and one N-atom, and more preferred are two C-atoms. The shared bond may be a single bond or a double bond;

formula I.3:



with

A, being the ring system of formula I.1;

C being a 3, 4, 5 or 6 membered second ring systems that is spiro fused to A and that beside the one atoms it shares with A consists only of carbon atoms and that may be saturated, partially saturated or aromatic whereby the ring system of formula I.3 may optionally be substituted by one or more

- 15 -

substituents selected independently of one another from the group R^2 and/or optionally substituted by one group R^3 and whereby the ring atom that is shared by the two ring systems A and C is a C-atom,

or

D is selected from the group D^{2b} consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl and cyclohexenyl, wherein the above-mentioned members of the group D^{2b} may optionally be substituted by one or more substituents selected independently of one another from the group R^4 ,

5 or

D is selected from the group D^{3b} consisting of C_{1-6} -alkyl wherein the above-mentioned C_{1-6} -alkyl-group may optionally be substituted by one or more substituents selected independently of one another from the group R^5 ,

or

D is selected from the group D^{4b} consisting of phenyl wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R^6 ,


10 or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R^6 .


- 16 -

In another preferred embodiment of the present invention


D is selected from the group D^{1c} consisting of heterocyclyl,
selected from the group of




- 17 -



X = O, S or N
 p = 1, 2, 3, 4 or 5
 q = 1, 2 or 3



X = O, S or N
 p = 1, 2, 3, 4 or 5
 q = 1, 2 or 3



X = O, S or N
 p = 1, 2, 3, 4 or 5
 q = 1, 2 or 3

wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of C₁₋₃-alkyl.

or

D is selected from the group D^{2c} consisting of cyclobutyl, cyclopentyl, and cyclohexyl,
 wherein the above-mentioned members of the group D^{2c} may optionally be substituted by one or more substituents selected independently of one another from the group R⁴,

or

5

D is selected from the group D^{3c} consisting of C₁₋₅-alkyl
 wherein the above-mentioned C₁₋₅-alkyl-group may optionally be substituted by one or more substituents selected independently of one another from the group R⁵,

or

D is selected from the group D^{4b} consisting of phenyl
 wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R⁶,

- 18 -

or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R⁶,

In another preferred embodiment of the present invention

D is selected from the group D^{1d} consisting of heterocyclyl, according to formula I.1 as defined above

5

or

D is selected from the group D^{2c} consisting of cyclobutyl, cyclopentyl, and cyclohexyl, wherein the above-mentioned members of the group D^{2c} may optionally be substituted by one or more substituents selected independently of one another from the group R⁴,

or

10

D is selected from the group D^{3d} consisting of 2-butyl- and 3-pentyl- wherein the above-mentioned group D^{3d} may optionally be substituted by one or more substituents selected independently of one another from the group R⁵,

or

D is selected from the group D^{4b} consisting of phenyl wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R⁶,

- 19 -

or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R⁶.

5 In another preferred embodiment of the present invention

D is selected from the group D^{1e} consisting of a monocyclic, non-aromatic, saturated heterocyclic group of 4 to 8, preferably 5, 6 or 7 ring atoms, whereby said ring atoms are carbon atoms and 1, 2 or 3 heteroatom(s), preferably 1 heteroatom, the heteroatom(s) being selected from oxygen, nitrogen and sulphur, the sulphur being in the form of – S(O)_r - with r being 0, 1 or 2, preferably with r being 0 and whereby preferably said heterocyclic group being attached to the scaffold by a carbon ring atom which is not directly attached to said ring heteroatom, wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of C₁₋₃-alkyl.

or

D is selected from the group D^{2c} consisting of cyclobutyl, cyclopentyl, and cyclohexyl, wherein the above-mentioned members of the group D^{2c} may optionally be substituted by one or more substituents selected independently of one another from the group R⁴,

10 or

D is selected from the group D^{3d} consisting of 2-butyl- and 3-pentyl- wherein the above-mentioned group D^{3d} may optionally be substituted by

- 20 -

one or more substituents selected independently of one another from the group R⁵,

or

D is selected from the group D^{4b} consisting of phenyl wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R⁶,

5 or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R⁶.

In another preferred embodiment of the present invention

D is selected from the group D^{1f} consisting of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl and piperazinyl, whereby preferably the tetrahydropyranyl is 3- or 4-tetrahydropyranyl, the tetrahydrofuranyl is 3-tetrahydrofuranyl, and the piperidinyl is 3- or 4-piperidinyl, wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of C₁₋₃-alkyl.

10 or

D is selected from the group D^{2c} consisting of cyclobutyl, cyclopentyl, and cyclohexyl, wherein the above-mentioned members of the group D^{2c} may optionally be substituted by one or more substituents selected independently of one

- 21 -

another from the group R⁴,

or

D is selected from the group D^{3d} consisting of 2-butyl- and 3-pentyl- wherein the above-mentioned group D^{3d} may optionally be substituted by one or more substituents selected independently of one another from the group R⁵,

5 or

D is selected from the group D^{4b} consisting of phenyl wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R⁶,

or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R⁶.

10

In another preferred embodiment of the present invention

D is selected from the group D^{1g} consisting of tetrahydropyranyl, tetrahydrofuranyl, piperidiny, and pyrrolindiny, whereby preferably the tetrahydropyranyl is 3- or 4-tetrahydropyranyl, the tetrahydrofuranyl is 3-tetrahydrofuranyl, and the piperidiny is 3- or 4-piperidiny, wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of C₁₋₃-alkyl.

or

- 22 -

D is selected from the group D^{2c} consisting of cyclobutyl, cyclopentyl, and cyclohexyl,
wherein the above-mentioned members of the group D^{2c} may optionally be substituted by one or more substituents selected independently of one another from the group R⁴,

or

D is selected from the group D^{3d} consisting of 2-butyl- and 3-pentyl-
wherein the above-mentioned group D^{3d} may optionally be substituted by one or more substituents selected independently of one another from the group R⁵,

5

or

D is selected from the group D^{4b} consisting of phenyl
wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R⁶,

or

10

D is selected from the group D^{5b} consisting of pyridyl
wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R⁶.

In another preferred embodiment of the present invention

D is selected from the group D^{1h} consisting of tetrahydropyranyl and tetrahydrofuranyl, preferably 3- or 4-tetrahydropyranyl and 3-

- 23 -

tetrahydrofuranyl,

wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of methyl.

or

D is selected from the group D^{2c} consisting of cyclobutyl, cyclopentyl, and cyclohexyl,

wherein the above-mentioned members of the group D^{2c} may optionally be substituted by one or more substituents selected independently of one another from the group R^4 ,

5 or

D is selected from the group D^{3d} consisting of 2-butyl- and 3-pentyl- wherein the above-mentioned group D^{3d} may optionally be substituted by one or more substituents selected independently of one another from the group R^5 ,

or

D is selected from the group D^{4b} consisting of phenyl wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R^6 ,

10

or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R^6 .

In another preferred embodiment of the present invention

R^1 is selected independently for each R^1 from the group R^{1b} consisting of Hydrogen, fluorine, F_3C- , F_3C-CH_2- , C_{1-6} -alkyl-, C_{1-3} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heterocyclyl-CO-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N-$, $R^{10}O-CO-$, $(R^9)_2N-CO-$, $R^{10}-CO-(R^{10})N-$, $(R^9)_2N-CO-(R^{10})N-$, $(R^9)_2N-CO-O-$, and $R^{10}-O-CO-(R^{10})N-$,

where the above-mentioned, members F_3C-CH_2- , C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heterocyclyl-CO-, and R^{10} -O- C_{1-3} -alkyl-, may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, HO-, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-6} -alkyl-O-, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}$ -alkyl-, $(R^{10})_2N-CO-$, C_{3-6} -cycloalkyl-, C_{3-6} -cycloalkyl- C_{1-4} -alkyl- and C_{1-6} -alkyl-.


5 In another preferred embodiment of the present invention

R^1 is selected independently for each R^1 from the group R^{1c} consisting of C_{1-6} -alkyl-, C_{1-3} -alkynyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heterocyclyl-CO-, $R^{10}O-CO-$, and $(R^9)_2N-CO-$,

where the above-mentioned, members C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, heteroaryl-, heterocyclyl-CO-, and heteroaryl- C_{1-6} -alkyl-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, HO-, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-6} -alkyl-O-, C_{1-6} -alkyl-, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}$ -alkyl-, C_{3-6} -cycloalkyl-, C_{3-6} -cycloalkyl- C_{1-4} -alkyl- and $(R^{10})_2N-CO-$,

In another preferred embodiment of the present invention


R^1 is selected independently for each R^1 from the group R^{1d} consisting of C_{1-3} -alkyl-, C_{1-3} -alkyl-O-CO-, HO-CO-, $(C_{1-6}$ -alkyl) $_2$ N-CO-, oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, thienyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, oxadiazolyl- C_{1-3} -alkyl-, oxazolyl- C_{1-3} -alkyl-, isoxazolyl- C_{1-3} -alkyl-, triazolyl- C_{1-3} -alkyl-, thiazolyl- C_{1-3} -alkyl-, pyrrolyl- C_{1-3} -alkyl-, furanyl- C_{1-3} -alkyl-, pyrazolyl- C_{1-3} -alkyl-, pyridyl- C_{1-3} -alkyl-, pyridazinyl- C_{1-3} -alkyl-, pyrimidinyl- C_{1-3} -alkyl-, pyrazolyl- C_{1-3} -alkyl-,



where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-3} -alkyl-O- and C_{1-3} -alkyl-.

In another preferred embodiment of the present invention

R^1 is selected independently for each R^{1e} from the group consisting of C_{1-3} -alkyl-, $(C_{1-6}$ -alkyl) $_2$ N-CO-, oxadiazolyl, pyrazolyl-methyl-,



where the above-mentioned, members may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F_3C -,

- 26 -

HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₃-alkyl-O- and C₁₋₃-alkyl-.

In another preferred embodiment of the present invention

R² is selected from the group R^{2b} consisting of
H-, fluorine, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of

fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

and in cases where D is a heterocyclyl group with NR² as ring member, R² shall be

independently of any other R²: H-, F₃C-CH₂-, HF₂C-CH₂-, C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-, and C₁₋₆-alkyl-SO₂-,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of

fluorine, HO-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, R¹⁰-O-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-.

In another preferred embodiment of the present invention

R² is selected from the group R^{2c} consisting of

- 27 -

H-, fluorine, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-6} -alkyl-, $(R^{10})_2N-CO-$, $R^{10}-CO-(R^{10})N-$,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, C_{1-6} -alkyl-,

and in cases where D is a heterocyclyl group with NR^2 as ring member, R^2 shall be

independently of any other R^2 : H-, F_3C-CH_2- , HF_2C-CH_2- , C_{1-6} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl, heteroaryl- C_{1-6} -alkyl-, $R^{10}-O-C_{1-3}$ -alkyl-, $R^{10}O-CO-$, $(R^{10})_2N-CO-$, $R^{10}-CO-$, and C_{1-6} -alkyl- SO_2- ,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, C_{1-6} -alkyl-.

In another preferred embodiment of the present invention

R^2 is selected from the group R^{2d} consisting of H- and C_{1-6} -alkyl-,

and in cases where D is a heterocyclyl group with NR^2 as ring member, R^2 shall be

independently of any other R^2 : H-, C_{1-6} -alkyl-, $R^{10}O-CO-$, $(R^{10})_2N-CO-$, $R^{10}-CO-$, phenyl- $CO-$ and phenyl- $O-CO-$,

where the above-mentioned members may optionally be substituted

- 28 -

independently of one another by one or more substituents selected from the group consisting of fluorine, C₁₋₆-alkyl-.

In another preferred embodiment of the present invention

R² is selected from the group R^{2e} consisting of H-, H₃C-,

In another preferred embodiment of the present invention

R³ is selected from the group R^{3b} consisting of H-, hydroxy, C₁₋₆-alkyl-O-, whereby C₁₋₆-alkyl-O- may optionally be substituted by one or more fluorine and/or one HO-.

5

In another preferred embodiment of the present invention

R³ is selected from the group R^{3c} consisting of H-.

In another preferred embodiment of the present invention

R⁴ is selected from the group R^{4b} consisting of H-, fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R¹⁰)₂N-CO-(R¹⁰)N- and R¹⁰-O-CO-(R¹⁰)N-,

where the above-mentioned members F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-,

- 29 -

C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₃-alkyl- and (R¹⁰)₂N-C₁₋₃-alkyl-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-.

In another preferred embodiment of the present invention

R⁴ is selected from the group R^{4c} consisting of H-, fluorine, F₃C-, C₁₋₆-alkyl-, aryl, HO-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₂₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, (R¹⁰)₂N-CO-(R¹⁰)N- and R¹⁰-O-CO-(R¹⁰)N-,

where the above-mentioned members C₁₋₆-alkyl-, aryl, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₂₋₃-alkyl- and (R¹⁰)₂N-C₁₋₃-alkyl- may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, C₁₋₃-alkyl-, and F₃C-.

In another preferred embodiment of the present invention

R⁴ is selected from the group R^{4d} consisting of H-, fluorine, methyl-, HO-, CH₃-O-, phenyl-, H₂N-, C₁₋₆-alkyl-O-CO-(H)N-, C₁₋₆-alkyl-CO-(H)N-, phenyl-CO-(H)N-,

where the above-mentioned members methyl-, CH₃-O-, phenyl-, H₂N-, C₁₋₆-alkyl-O-CO-(H)N-, C₁₋₆-alkyl-CO-(H)N-, phenyl-CO-(H)N- may optionally be substituted independently of one another by one or more fluorine.

In another preferred embodiment of the present invention

R^4 is selected from the group R^{4e} consisting of H-, and fluorine.

In another preferred embodiment of the present invention

R^5 is selected from the group R^{5b} consisting of H-, fluorine, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $R^{10}O$ -CO-, $(R^{10})_2N$ -CO-, R^{10} -CO- $(R^{10})N$ -, R^{10} -CO-, $(R^{10})_2N$ -CO- $(R^{10})N$ -, and R^{10} -O-CO- $(R^{10})N$ -,

where the above-mentioned, members HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, R^{10} -O- C_{1-3} -alkyl-, and $(R^{10})_2N$ - C_{1-3} -alkyl- may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O_2N -, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, HO- C_{1-6} -alkyl-, C_{1-6} -alkyl-O-, C_{1-6} -alkyl-O- C_{1-6} -alkyl-, C_{1-6} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, and $(R^{10})_2N$ -CO-,

5 In another preferred embodiment of the present invention

R^5 is selected from the group R^{5c} consisting of H-, fluorine, F_3C -, C_{1-6} -alkyl aryl, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $(R^{10})_2N$ -CO-, R^{10} -CO- $(R^{10})N$ -, $(R^{10})_2N$ -CO- $(R^{10})N$ -, and R^{10} -O-CO- $(R^{10})N$ -,

where the above-mentioned, members C_{1-6} -alkyl-, aryl- R^{10} -O- C_{1-3} -alkyl-,

- 31 -

and $(R^{10})_2N-C_{1-3}\text{-alkyl-}$ may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, $NC-$, F_3C- , and $C_{1-6}\text{-alkyl-}$,

In another preferred embodiment of the present invention

R^5 is selected from the group R^{5d} consisting of H- and fluorine,

In another preferred embodiment of the present invention

R^6 is selected from the group R^{6b} consisting of H-, fluorine, chlorine, bromine, $HO-$, $NC-$, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , carboxy-, $C_{1-6}\text{-alkyl-}$, $C_{1-6}\text{-alkyl-S-}$, $C_{1-6}\text{-alkyl-S-}C_{1-3}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{1-6}\text{-alkyl}$ $C_{3-7}\text{-heterocyclyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{1-6}\text{-alkyl-}$, aryl, aryl- $C_{1-6}\text{-alkyl-}$, heteroaryl-, heteroaryl- $C_{1-6}\text{-alkyl-}$, $R^{10}\text{-O-}$, $R^{10}\text{-O-}C_{1-3}\text{-alkyl-}$, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}\text{-alkyl-}$, $R^{10}\text{-O-CO-}$, $(R^{10})_2N\text{-CO-}$, $R^{10}\text{-CO-}(R^{10})N-$, $R^{10}\text{-CO-}$, $(R^{10})_2N\text{-CO-}(R^{10})N-$, and $R^{10}\text{-O-CO-}(R^{10})N-$,

where the above-mentioned, members HF_2C- , FH_2C- , F_3C-CH_2- , $C_{1-6}\text{-alkyl-}$, $C_{1-6}\text{-alkyl-S-}C_{1-3}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}$, $C_{3-7}\text{-cycloalkyl-}C_{1-6}\text{-alkyl}$ $C_{3-7}\text{-heterocyclyl-}$, $C_{3-7}\text{-heterocyclyl-}C_{1-6}\text{-alkyl-}$, aryl, aryl- $C_{1-6}\text{-alkyl-}$, heteroaryl-, heteroaryl- $C_{1-6}\text{-alkyl-}$, $R^{10}\text{-O-}C_{1-3}\text{-alkyl-}$ and $(R^{10})_2N-C_{1-3}\text{-alkyl-}$, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, $NC-$, O_2N- , F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , $HO-C_{1-6}\text{-alkyl-}$, $C_{1-6}\text{-alkyl-O-}$, $C_{1-6}\text{-alkyl-O-}C_{1-6}\text{-alkyl-}$, $C_{1-6}\text{-alkyl-}$, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}\text{-alkyl-}$, and $(R^{10})_2N\text{-CO-}$,

5 In another preferred embodiment of the present invention

R^6 is selected from the group R^{6c} consisting of H-, fluorine, chlorine, bromine, $HO-$, $NC-$, F_3C- , $C_{1-6}\text{-alkyl-}$, $C_{1-6}\text{-alkyl-S-}$, $C_{1-6}\text{-alkyl-S-}C_{1-3}\text{-alkyl-}$, $C_{3-7}\text{-cycloalkyl-}$, $C_{3-7}\text{-heterocyclyl-}$, aryl heteroaryl-,

- 32 -

R^{10} -O-, R^{10} -O-C₁₋₃-alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ -C₁₋₃-alkyl-, R^{10} O-CO-, $(R^{10})_2N$ -CO- and R^{10} -CO- $(R^{10})N$ -,

where the above-mentioned, members C₁₋₆-alkyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-heterocyclyl-, aryl, heteroaryl-, R^{10} -O-C₁₋₃-alkyl- and $(R^{10})_2N$ -C₁₋₃-alkyl-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, F₃C-, and C₁₋₆-alkyl-,

In another preferred embodiment of the present invention

R^6 is selected from the group R^{6d} consisting of H-, fluorine, chlorine, bromine, F₃C-, C₁₋₆-alkyl-, and R^{10} -O-,

where the above-mentioned, member C₁₋₆-alkyl-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine,

In another preferred embodiment of the present invention

R^6 is selected from the group R^{6e} consisting of H-, fluorine, chlorine, bromine, F₃C-, H₃C-, and H₃C-O-,

where the above-mentioned, member H₃C-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine,

5

In another preferred embodiment of the present invention

R^9 is selected independently for each R^9 from the group R^{9b} consisting of H-, C₁₋₆-alkyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, and heteroaryl-C₁₋₃-alkyl-, where the above-mentioned members C₁₋₆-alkyl-, C₂₋₆-alkinyl-, C₃₋

- 33 -

7-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, and heteroaryl-C₁₋₃-alkyl- may optionally be substituted independently of one another by one or more substituents selected independently from one another from the group consisting of fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-O- and C₁₋₆-alkyl-.

In another preferred embodiment of the present invention

R⁹ is selected independently for each R⁹ from the group R^{9c} consisting of H-, C₁₋₆-alkyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, aryl and heteroaryl, and where the above-mentioned members C₁₋₆-alkyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, aryl and heteroaryl may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, and C₁₋₆-alkyl-O- and C₁₋₆-alkyl-.

In another preferred embodiment of the present invention

R⁹ is selected independently for each R⁹ from the group R^{9d} consisting of H-, C₁₋₆-alkyl-, phenyl, and pyridyl, and where the above-mentioned members C₁₋₆-alkyl-, phenyl, and pyridyl may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-O- and C₁₋₆-alkyl-.

- 34 -

In another preferred embodiment of the present invention

R^9 is selected independently for each R^9 from the group R^{9e} consisting of H-, methyl-, ethyl- and tert.-butyl, and

where the above-mentioned members methyl-, ethyl- and tert.-butyl may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine.

In another preferred embodiment of the present invention

R^{10} is selected independently for each R^{10} from the group R^{10b} consisting of H- (but not in case is part of a group being selected from $R^{10}O-CO-$, $R^{10}-SO_2-$ or $R^{10}-CO-$), C_{1-6} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-3} -alkyl-, aryl and heteroaryl,

and in case where two R^{10} groups both are bound to the same nitrogen atom they may together with said nitrogen atom form a 3 to 12 membered heterocyclyl ring, and wherein one of the $-CH_2$ -groups of the heterocyclic ring formed may be replaced by $-O-$, $-NH-$, $-N(C_{3-6}$ -cycloalkyl)-, $-N(C_{3-6}$ -cycloalkyl- C_{1-4} -alkyl)- or $-N(C_{1-4}$ -alkyl)- and

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, $NC-$, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , CH_3-O-C_{1-6} -alkyl-, C_{1-6} -alkyl-, and C_{1-6} -alkyl- $O-$.

5 In another preferred embodiment of the present invention

R^{10} is selected independently for each R^{10} from the group R^{10c} consisting of H- (but not in case is part of a group being selected from $R^{10}O-CO-$, $R^{10}-$

- 35 -

SO₂- or R¹⁰-CO-), C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-, aryl and heteroaryl,

and in case where two R¹⁰ groups both are bound to the same nitrogen atom they may together with said nitrogen atom form a 3 to 12 membered heterocyclyl ring, and wherein one of the -CH₂-groups of the heterocyclic ring formed may be replaced by -O-, -NH-, -N(C₃₋₆-cycloalkyl)-, -N(C₃₋₆-cycloalkyl-C₁₋₄-alkyl)- or -N(C₁₋₄-alkyl)- and

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, and C₁₋₆-alkyl-O-.

In another preferred embodiment of the present invention

R¹⁰ is selected independently for each R¹⁰ from the group R^{10d} consisting of H- (but not in case is part of a group being selected from R¹⁰O-CO-, R¹⁰-SO₂- or R¹⁰-CO-), C₁₋₆-alkyl-, phenyl, and pyridyl,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
fluorine, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, and C₁₋₆-alkyl-O-.

In another preferred embodiment of the present invention

R¹⁰ is selected independently for each R¹⁰ from the group R^{10e} consisting of H- (but not in case is part of a group being selected from R¹⁰O-CO-, R¹⁰-SO₂- or R¹⁰-CO-), methyl-, ethyl- and tert.-butyl,

- 36 -

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine.

Any and each of the above definitions for x, y, L, D and R¹ to R¹⁰ may be combined with each other.

5 In another preferred embodiment of the present invention

D is selected from the group consisting of cyclopentyl, cyclohexyl, 3-pentyl-, phenyl, tetrahydropyranyl, tetrahydrofuranyl and pyridyl, wherein the above-mentioned cyclopentyl, cyclohexyl, 3-pentyl-, phenyl, and pyridyl groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine or methyl and wherein the above-mentioned tetrahydropyranyl and tetrahydrofuranyl groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of methyl.

L is selected from the integers 0, 1 and 2,

x is selected from the integers 0, 1, 2 and 3 ,

y is 0,


10

and

R¹ is selected independently for each R¹ from the group R^{1d} consisting of C₁₋₃-alkyl-, C₁₋₃-alkyl-O-CO-, HO-CO-, (C₁₋₆-alkyl)₂N-CO-, oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, thienyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, oxadiazolyl-C₁₋₃-alkyl-, oxazolyl-C₁₋₃-alkyl-, isoxazolyl-C₁₋₃-alkyl-, triazolyl-C₁₋₃-alkyl-, thiazolyl-C₁₋₃-alkyl-, pyrrolyl-C₁₋₃-alkyl-, furanyl-C₁₋₃-alkyl-, pyrazolyl-C₁₋₃-alkyl-, pyridyl-C₁₋₃-alkyl-,

- 37 -

pyridazinyl-C₁₋₃-alkyl-, pyrimidinyl-C₁₋₃-alkyl-, pyrazolyl-C₁₋₃-alkyl-,



where the above-mentioned, members may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₃-alkyl-O- and C₁₋₃-alkyl-.

In another preferred embodiment of the present invention

D is selected from the group consisting of cyclopentyl, cyclohexyl, 3-pentyl-, phenyl and pyridyl,

wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine or methyl.

5 L is 1,


x is selected from the integers 1 and 2,

y is 0,

and

R¹ is selected independently for each R^{1e} from the group consisting of C₁₋₃-alkyl-, (C₁₋₆-alkyl)₂N-CO-, oxadiazolyl, pyrazolyl-methyl-,

- 38 -



where the above-mentioned, members may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-3} -alkyl-O- and C_{1-3} -alkyl-.

In another preferred embodiment of the invention in the two directly above mentioned embodiments

D is selected from the group consisting of cyclopentyl, cyclohexyl and pyridyl, wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine or methyl.

- 5 The following matrix I shows further embodiments of the inventions that are considered preferred. L, x and y are as defined below.

Matrix I:

$D^{1b/2b/3b/4b/5b}/R^{1b}/$ $R^{2b}/R^{3b}/R^{4b}/R^{5b}/$ $R^{6b}/R^{9b}/R^{10b}$	$D^{1c/2c/3c/4b/5b}/R^{1c}/$ $R^{4c}/R^{5c}/R^{6c}/R^{9c}/$ R^{10c}			
$D^{1d/2c/3d/4b/5b}/R^{1d}/$ $R^{2d}/R^{3c}/R^{4d}/R^{5d}/$ $R^{6d}/R^{9d}/R^{10d}$	$D^{1e/2c/3d/4b/5b}/R^{1e}/$ $R^{4e}/R^{5d}/R^{6e}/R^{9e}/$ R^{10e}	$D^{1f/2c/3d/4b/5b}/R^{1e}/$ $R^{4e}/R^{5d}/R^{6e}/R^{9e}/$ R^{10e}	$D^{1g/2c/3d/4b/5b}/R^{1e}/$ $R^{4e}/R^{5d}/R^{6e}/R^{9e}/$ R^{10e}	$D^{1h/2c/3d/4b/5b}/R^{1e}/$ $R^{4e}/R^{5d}/R^{6e}/R^{9e}/$ R^{10e}
$D^{1h/2c/3d/4b/5b}/R^{1a}/$ $R^{4a}/R^{5a}/R^{6a}/R^{9a}/$ R^{10a}	$D^{1h/2c/3d/4b/5b}/R^{1b}/$ $R^{4b}/R^{5b}/R^{6b}/R^{9b}/$ R^{10b}	$D^{1h/2c/3d/4b/5b}/R^{1c}/$ $R^{4c}/R^{5c}/R^{6c}/R^{9c}/$ R^{10c}	$D^{1h/2c/3d/4b/5b}/$ $R^{1d}/R^{4d}/R^{5d}/R^{6d}/$ R^{9d}/R^{10d}	$D^{1h/2c/3d/4b/5b}/R^{1e}/$ $R^{4e}/R^{5d}/R^{6e}/R^{9e}/$ R^{10e}

- 39 -

$D^{1a}/R^{1a}/R^{2a}/R^{3a}/R^{9a}/R^{10a}$	$D^{1a}/R^{1b}/R^{2b}/R^{3b}/R^{9b}/R^{10b}$	$D^{1a}/R^{1c}/R^{2c}/R^{3c}/R^{9c}/R^{10c}$	$D^{1a}/R^{1d}/R^{2d}/R^{3c}$	$D^{1a}/R^{1e}/R^{2e}/R^{3c}$
$D^{1b}/R^{1a}/R^{2a}/R^{3a}/R^{9a}/R^{10a}$	$D^{1b}/R^{1b}/R^{2b}/R^{3b}/R^{9b}/R^{10b}$	$D^{1b}/R^{1c}/R^{2c}/R^{3c}/R^{9c}/R^{10c}$	$D^{1b}/R^{1d}/R^{2d}/R^{3c}$	$D^{1b}/R^{1e}/R^{2e}/R^{3c}$
$D^{1c}/R^{1a}/R^{9a}/R^{10a}$	$D^{1c}/R^{1b}/R^{9b}/R^{10b}$	$D^{1c}/R^{1c}/R^{9c}/R^{10c}$	D^{1c}/R^{1d}	D^{1c}/R^{1e}
$D^{1d}/R^{1a}/R^{2a}/R^{3a}/R^{9a}/R^{10a}$	$D^{1d}/R^{1b}/R^{2b}/R^{3b}/R^{9b}/R^{10b}$	$D^{1d}/R^{1c}/R^{2c}/R^{3c}/R^{9c}/R^{10c}$	$D^{1d}/R^{1d}/R^{2d}/R^{3c}$	$D^{1d}/R^{1e}/R^{2e}/R^{3c}$
$D^{1e}/R^{1a}/R^{9a}/R^{10a}$	$D^{1e}/R^{1b}/R^{9b}/R^{10b}$	$D^{1e}/R^{1c}/R^{9c}/R^{10c}$	D^{1e}/R^{1d}	D^{1e}/R^{1e}
$D^{1f}/R^{1a}/R^{9a}/R^{10a}$	$D^{1f}/R^{1b}/R^{9b}/R^{10b}$	$D^{1f}/R^{1c}/R^{9c}/R^{10c}$	D^{1f}/R^{1d}	D^{1f}/R^{1e}
$D^{1g}/R^{1a}/R^{9a}/R^{10a}$	$D^{1g}/R^{1b}/R^{9b}/R^{10b}$	$D^{1g}/R^{1c}/R^{9c}/R^{10c}$	D^{1g}/R^{1d}	D^{1g}/R^{1e}
$D^{1h}/R^{1a}/R^{9a}/R^{10a}$	$D^{1h}/R^{1b}/R^{9b}/R^{10b}$	$D^{1h}/R^{1c}/R^{9c}/R^{10c}$	D^{1h}/R^{1d}	D^{1h}/R^{1e}







and the salts thereof, preferably pharmaceutically acceptable salts thereof, solvates thereof or the solvates of the aforementioned salts thereof.











Within the meaning of the present invention the term










- 5 “ $D^{1b/2b/3b/4b/5b}/R^{1b}/R^{2b}/R^{3b}/R^{4b}/R^{5b}/R^{6b}/R^{9b}/R^{10b}$ ” as given in above table embraces all such compounds of formula (I) wherein the substituent represented in formula (I) by “D” is selected from one of the groups defined by D^{1b} , D^{2b} , D^{3b} , D^{4b} and D^{5b} , the substituent represented by R^1 is selected from one of the groups defined by R^{1b} , the substituent represented by R^2 is selected from one of the groups defined by R^{2b} , the
- 10 substituent represented by R^4 is selected from one of the groups defined by R^{4b} , the substituent represented by R^5 is selected from one of the groups defined by R^{5b} , the substituent represented by R^6 is selected from one of the groups defined by R^{6b} , the substituent represented by R^9 is selected from one of the groups defined by R^{9b} , and the substituent represented by R^{10} is selected from one of the groups defined by
- 15 R^{10b} .











For all embodiments L is selected from the integers 0, 1, 2 and 3, preferably 1 and 2;
 x is selected from the integers 0, 1, 2, 3 and 4, preferably 0, 1, 2 and 3, more preferably 1 and 2; y is selected from the integers 0, 1 and 2, preferably 0 and 1.











- 5 In another preferred embodiment of the present invention related to the compounds of formulae 1 through 47 as listed below in table 1



No.	Compound	No.	Compound
1		2	
3		4	
5		6	

7		8	
9		10	
11		12	
13		14	
15		16	

17		18	
19		20	
21		22	
23			
24		25	

26		27	
28		29	
30		31	
32		33	
34		35	

36		37	
38		39	
40		41	
42		43	
44		45	

46		47	
----	---	----	---

and the salts thereof, preferably pharmaceutically acceptable salts thereof, solvates thereof or the solvates of the aforementioned salts thereof.

Table 1.

5

USED TERMS AND DEFINITIONS

Terms not specifically defined herein should be given the meanings that would be given to them by a person skilled in the art in light of the disclosure and the context. Examples include that specific substituents or atoms are presented with their 1 or 2 letter code, like H for hydrogen, N for nitrogen, C for carbon, O for oxygen, S for sulphur and the like. Optionally but not mandatorily the letter is followed by a hyphen to indicate a bond. As used in the specification, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

10

15

20

25

In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C₁₋₆ alkyl means an alkyl group or alkyl radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for example, "alkyl-O-" means a monovalent radical of the formula alkyl-O-, which is attached via the oxygen atom (alkoxy). If the term of a substituent starts or ends with a minus sign or hyphen, i.e. -, this sign emphasises the attachment point like in the aforementioned example alkyl-O-, where the "O" is linked to the group of which the alkyl-O- is a substituent. Unless otherwise specified below, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.

In general, all "**tautomeric forms and isomeric forms and mixtures**", whether individual geometric isomers or optical isomers or racemic or non-racemic mixtures of isomers, of a chemical structure or compound are intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or
5 structure.

The term "**substituted**" as used herein explicitly or implicitly, means that any one or more hydrogen(s) on the designated atom is replaced with a member of the indicated group of substituents, provided that the designated atom's normal valence is not exceeded. In case a substituent is bound via a double bond, e.g. an oxo substituent, such substituent replaces two hydrogen atoms on the designated atom. The substitution shall result in a stable compound. "Stable" in this context preferably means a compound that from a pharmaceutical point of view is chemically and physically sufficiently stable in order to be used as an active pharmaceutical
10 ingredient of a pharmaceutical composition.

If a substituent is not defined, it shall be hydrogen.

By the term "**optionally substituted**" is meant that either the corresponding group is substituted or it is not. Accordingly, in each occasion where this term is used, the
20 non-substituted variation is a more pronounced aspect of the invention, i.e. preferably there are no such optional substituents.

The phrase "**pharmaceutically acceptable**" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the
25 scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, "**pharmaceutically acceptable salt(s)**" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or
30 base salts thereof. Preferably addition salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic

- 47 -

acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; and the salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pantoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, isethionic acid, and the like. As the compounds of the present invention may have both, acid as well as basic groups, those compounds may therefore be present as internal salts too.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.

“Prodrugs” are considered compounds that release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.


Prodrugs according to the present invention are prepared by modifying functional groups present in the compound in such a way that these modifications are retransformed to the original functional groups under physiological conditions.. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bound to any group that, when the prodrug of the present invention is administered to a mammalian subject, is retransformed to free said hydroxyl, amino, or sulfhydryl group. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.

- 48 -


“Metabolites” are considered as derivatives of the compounds according to the present invention that are formed in vivo. Active metabolites are such metabolites that cause a pharmacological effect. It will be appreciated that metabolites of the compounds according to the present inventions are subject to the present invention as well, in particular active metabolites.

Some of the compounds may form **“solvates”**. For the purposes of the invention the term “solvates” refers to those forms of the compounds which form, in the solid or liquid state, a complex by coordination with solvent molecules. Hydrates are a specific form of solvates in which the coordination takes place with water. According to the present invention, the term preferably is used for solid solvates, such as amorphous or more preferably crystalline solvates.

“Scaffold”: The scaffold of the compounds according to the present invention is represented by the following core structure, the numeration of the ring members thereof is indicated in bold:




It will be evident for the skilled person in the art, that this scaffold can be described by its tautomeric “enol” form



- 49 -

In the context of the present invention both structural representations of the scaffold shall be considered the subject of the present invention, even if only one of the two representatives is presented. It is believed that for the majority of compounds under ambient conditions and therewith under conditions which are the relevant conditions for a pharmaceutical composition comprising said compounds, the equilibrium of the tautomeric forms lies on the side of the pyrazolopyrimidin-4-one representation. Therefore, all embodiments are presented as pyrazolopyrimidin-4-one-derivatives or more precisely as pyrazolo[3,4-d]pyrimidin-4-one derivatives.

- 10 **"Bonds"**: If within a chemical formula of a ring system or a defined group a substituent is directly linked to an atom or a group like "RyR" in below formula this shall mean that the substituent is only attached to the corresponding atom. If however from another substituent like "RxR" a bond is not specifically linked to an atom of the ring system but drawn towards the centre of the ring or group this means
15 that this substituent "RxR" may be linked to any meaningful atom of the ring system / group unless stated otherwise.



- The bond symbol "-" (= minus sign) or the symbol "-*" (= minus sign followed by an asterisk sign) stands for the bond through which a substituent is bound to the corresponding remaining part of the molecule / scaffold. In cases in that minus sign does not seem to be sufficiently clear, an asterisk is added to the bond symbol "-" in order to determine the point of attachment of said bond with the corresponding main part of the molecule / scaffold.
- 20
- 25 In general, the bond to one of the herein defined heterocyclyl or heteroaryl groups may be effected via a C atom or optionally an N atom.

The term “**aryl**” used in this application denotes a phenyl, biphenyl, indanyl, indenyl, 1,2,3,4-tetrahydronaphthyl or naphthyl group, preferably it denotes a phenyl or naphthyl group, more preferably a phenyl group. This definition applies for the use of “**aryl**” in any context within the present description in the absence of a further definition.

The term “**C_{1-n}-alkyl**” denotes a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms, wherein n is a figure selected from the group of 2, 3, 4, 5, 6, 7, 8, 9, or 10, preferably from the group of 2, 3, 4, 5, or 6, more preferably from the group of 2, 3, or 4. Examples of such groups include methyl, ethyl, *n*-propyl, *iso*-propyl, butyl, *iso*-butyl, *sec*-butyl, *tert*-butyl, *n*-pentyl, *iso*-pentyl, *neo*-pentyl, *tert*-pentyl, *n*-hexyl, *iso*-hexyl etc. As will be evident from the context, such **C_{1-n}-alkyl** group optionally can be substituted.

This definition applies for the use of “**alkyl**” in any reasonable context within the present description in the absence of a further definition.

In cases in which the term “**C_{1-n}-alkyl**” is used in the middle of two other groups / substituents, like for example in “**C_{1-n}cycloalkyl-C_{1-n}-alkyl-O-**”, this means that the “**C_{1-n}-alkyl**”-moiety bridges said two other groups. In the present example it bridges the C_{1-n}cycloalkyl with the oxygen like in “cyclopropyl-methyl-oxy-“. It will be evident, that in such cases “**C_{1-n}-alkyl**” has the meaning of a “**C_{1-n}-alkylene**” spacer like methylene, ethylene etc. The groups that are bridged by “**C_{1-n}-alkyl**” may be bound to “**C_{1-n}-alkyl**” at any position thereof. Preferably the right hand group is located at the distal right hand end of the alkyl group and left hand group at the distal left hand side of the alkyl group. The same applies for other substituents.

The term “**C_{2-n}-alkenyl**” denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and at least one C=C group (i.e. carbon – carbon double bond), wherein n preferably has a value selected from the group of 3, 4, 5, 6, 7, or 8, more preferably 3, 4, 5, or 6, more preferably 3 or 4. Examples of such groups include ethenyl, 1-propenyl, 2-propenyl, *iso*-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl etc.. As will be evident from the context, such **C_{2-n}-alkenyl** group optionally can be substituted.

This definition applies for the use of “**alkenyl**” in any reasonable context within the present description in the absence of a further definition.

In cases in which the term “**C_{2-n}-alkenyl**” is used in the middle of two other groups / substituents, the analogue definition as for C_{1-n}-alkyl applies.

5

The term “**C_{2-n}-alkynyl**” denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and at least one C≡C group (i.e. a carbon-carbon triple bond), wherein n preferably has a value selected from the group of 3, 4, 5, 6, 7, or 8, more preferably 3, 4, 5, or 6, more preferably 3 or 4. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl etc.. As will be evident from the context, such **C_{2-n}-alkynyl** group optionally can be substituted.

10

This definition applies for the use “**alkynyl**” in any reasonable context within the present description in the absence of a further definition.

15

In cases in which the term “**C_{2-n}-alkynyl**” is used in the middle of two other groups / substituents, the analogue definition as for C_{1-n}-alkyl applies.

The term “**C_{3-n}-cycloalkyl**” denotes a saturated monocyclic group with 3 to n C ring atoms. n preferably has a value of 4 to 8 (= 4, 5, 6, 7, or 8), more preferably 4 to 7, more preferably such C_{3-n}-cycloalkyl is 5 or 6 membered. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc.. This definition applies for “**cycloalkyl**” in any reasonable context within the present description in the absence of a further definition.

20

25

The term “**halogen**” denotes an atom selected from among F, Cl, Br, and I.

The term “**heteroaryl**” used in this application denotes a heterocyclic, mono- or bicyclic aromatic ring system which includes within the ring system itself in addition to at least one C atom one or more heteroatom(s) independently selected from N, O, and/or S. A monocyclic ring system preferably consists of 5 to 6 ring members, a bicyclic ring system preferably consists of 8 to 10 ring members. Preferred are

30

- 52 -

heteroaryls with up to 3 heteroatoms, more preferred up to 2 heteroatoms, more preferred with 1 heteroatom. Preferred heteroatom is N. Examples of such moieties are benzimidazolyl, benzisoxazolyl, benzo[1,4]-oxazinyl, benzoxazol-2-onyl, benzofuranyl, benzoisothiazolyl, 1,3-benzodioxolyl, benzothiadiazolyl, benzothiazolyl, 5 benzothienyl, benzoxadiazolyl, benzoxazolyl, chromanyl, chromenyl, chromonyl, cinnolinyl, 2,3-dihydrobenzo[1,4]dioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydrobenzo[1,4]oxazinyl, 2,3-dihydroindolyl, 1,3-dihydroisobenzofuranyl, 2,3-dihydroisoindolyl, 6,7-dihydropyrrolizinyl, dihydroquinolin-2-onyl, dihydroquinolin-4-onyl, furanyl, imidazo[1,2-*a*]pyrazinyl, imidazo[1,2-*a*]pyridyl, imidazolyl, 10 imidazopyridyl, imidazo[4,5-*d*]thiazolyl, indazolyl, indolizinyl, indolyl, isobenzofuranyl, isobenzothienyl, isochromanyl, isochromenyl, isoindoyl, isoquinolin-2-onyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, 1,2,4-oxadiazoyl, 1,3,4-oxadiazoyl, 1,2,5-oxadiazoyl, oxazolopyridyl, oxazolyl, 2-oxo-2,3-dihydrobenzimidazolyl, 2-oxo-2,3-dihydroindolyl, 1-oxoindanyl, phthalazinyl, 15 pteridinyl, purinyl, pyrazinyl, pyrazolo[1,5-*a*]pyridyl, pyrazolo[1,5-*a*]pyrimidinyl, pyrazolyl, pyridazinyl, pyridopyrimidinyl, pyridyl (pyridinyl), pyridyl-*N*-oxide, pyrimidinyl, pyrimidopyrimidinyl, pyrrolopyridyl, pyrrolopyrimidinyl, pyrrolyl, quinazolinyl, quinolin-4-onyl, quinolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, tetrazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-20 thiadiazolyl, thiazolyl, thieno[2,3-*d*]imidazolyl, thieno[3,2-*b*]pyrrolyl, thieno[3,2-*b*]thiophenyl, thienyl, triazinyl, or triazolyl.

Preferred heteroaryl groups are oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, thienyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl, and pyrimidinyl, more 25 preferred is oxadiazolyl, pyrazolyl and pyridyl.

The definition pyrazole includes the isomers 1H-, 3H- and 4H-pyrazole. Preferably pyrazolyl denotes 1H-pyrazolyl.

30 The definition imidazole includes the isomers 1H-, 2H- and 4H-imidazole. A preferred definition of imidazolyl is 1H-imidazolyl.

- 53 -

The definition triazole includes the isomers 1H-, 3H- and 4H-[1,2,4]-triazole as well as 1H-, 2H- and 4H-[1,2,3]-triazole. The definition triazolyl therefore includes 1H-[1,2,4]-triazol-1-, -3- and -5-yl, 3H-[1,2,4]-triazol-3- and -5-yl, 4H-[1,2,4]-triazol-3-, -4- and -5-yl, 1H-[1,2,3]-triazol-1-, -4- and -5-yl, 2H-[1,2,3]-triazol-2-, -4- and -5-yl as well as 4H-[1,2,3]-triazol-4- and -5-yl.

The term tetrazole includes the isomers 1H-, 2H- and 5H-tetrazole. The definition tetrazolyl therefore includes 1H-tetrazol-1- and -5-yl, 2H-tetrazol-2- and -5-yl and 5H-tetrazol-5-yl.

The definition indole includes the isomers 1H- and 3H-indole. The term indolyl preferably denotes 1H-indol-1-yl.

The term isoindole includes the isomers 1H- and 2H-isoindole.

This definition applies for “**heteroaryl**” in any reasonable context within the present description in the absence of a further definition.

The term “**heterocyclyl**” within the context of the present invention denotes a saturated or unsaturated but non-aromatic monocyclic 3 to 8 membered, preferably 5-, 6- or 7-membered ring or a 5-12 membered saturated or unsaturated but non-aromatic bicyclic ring system (including spirocyclic and annealed ring systems), which include 1, 2, 3 or 4 heteroatoms, selected from N, O, and/or S, as defined by –S(O)_r- with r being 0, 1 or 2. Preferred are 1, 2, or 3 heteroatoms.


Preferred are saturated heterocyclyl rings with 5, 6, or 7 ring atoms, of which 1 or 2 are heteroatoms and the remaining are C-atoms. Such heterocyclyl groups are addressed as C₅₋₇-heterocyclyl.









Preferred examples for heterocycloalkyl include morpholinyl, piperidinyl, piperazinyl, thiomorpholinyl, oxathianyl, dithianyl, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dioxolanyl, oxathiolanyl, imidazolidinyl, tetrahydropyranyl, pyrrolinyl, tetrahydrothienyl, oxazolidinyl, homopiperazinyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, azetidiny, 1,3-diazacyclohexanyl or pyrazolidinyl group.

The heterocyclyl group may be bound to the rest of the molecule in more than one way. If no particular bonding arrangement is specified, then all possible arrangements are intended. For example, the term "tetrahydropyranyl" includes 2-, 3-, or 4- tetrahydropyranyl and the like. In cases with more than one ring, the bonding to the rest of the molecule is via at least one ring atom of the ring comprising the at least one heteroatom.

The order of preference of heterocyclic ring systems is: monocyclic ring are more preferred than bicyclic ring systems.

Examples for heterocyclic are the following groups:





X = O, S or N

X = O, S or N

X = O, S or N

$$p = 1, 2, 3, 4 \text{ or } 5$$

$p = 1, 2, 3, 4$
or 5

$p = 1, 2, 3, 4$
or 5


 $q = 1, 2 \text{ or } 3$ $q = 1, 2 \text{ or } 3$ $q = 1, 2 \text{ or } 3$

The above definition applies for “**heterocyclyl**” in any reasonable context within the present description in the absence of a further definition.

- 5 The following schemes shall illustrate a process to manufacture the compounds of the present invention by way of example:

- 56 -


Scheme 1



Scheme 1: In a first step 2-ethoxymethylene-malononitrile is condensed with mono-substituted hydrazines by heating in an appropriate solvent like ethanol in the presence of a base (e.g. triethylamine) to form 5-amino-1H-pyrazole-4-carbonitriles. These compounds are converted in a second step to the corresponding amides, e.g. by treatment of an ethanolic solution with ammonia (25 % in water) and hydrogen peroxide (35 % in water). In a third step, heating with carboxylic esters under basic conditions (e.g sodium hydride in ethanol) or carboxylic acids with an activation reagent (e.g. polyphosphoric acid) leads to pyrazolo[3,4-d]pyrimidin-4-ones as final products [cf., for example, A. Miyashita *et al.*, *Heterocycles* **1990**, 31, 1309ff].


Further alternative processes for preparing pyrazolo[3,4-d]pyrimidin-4-ones are known in the art and can likewise be employed for synthesizing the compounds of the invention (see, for example: P. Schmidt *et al.*, *Helvetica Chimica Acta* **1962**, 189, 1620ff.).

The mono-substituted hydrazine derivatives, that are used in step 1 of scheme 1 can be prepared by reductive amination of a ketone with hydrazinecarboxylic acid tert-butyl ester followed by a deprotection step as shown in scheme 2 [cf., for example, J.W. Timberlake *et al.*, "Chemistry of Hydrazo-, Azo-, and Azoxy Groups"; Patai, S., Ed.; 1975, Chapter 4; S. C. Hung *et al.*, *Journal of organic Chemistry* 1981, 46, 5413-5414].

Scheme 2

$n = 1, 2, 3$

Scheme 3 illustrates as a further example the preparation of compounds of formula I. Di-esters are reacted with 5-amino-1H-pyrazole-4-carboxamides and the intermediate formed is subsequently saponified using aqueous sodium hydroxide. The carboxylic acid formed can be reacted with an amine in an amide coupling-reaction after activation, e.g. by TBTU.

Scheme 3

with

TBTU = O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate

Further information also can be found in WO04099210 (in particular page 9, last paragraph to page 14, line 8, incorporated by reference).

- 5 The compounds of the invention show a valuable range of pharmacological effects which could not have been predicted. They are characterised in particular by inhibition of PDE9A.

10 Preferably the compounds according to the present invention show a high selectivity profile in view of inhibiting or modulating specific members within the PDE9 family or other PDE families, with a clear preference (selectivity) towards PDE9A inhibition.

The compounds of the present invention are supposed to show a favourable safety profile.

METHOD OF TREATMENT

The present invention refers to compounds, which are considered effective and selective inhibitors of phosphodiesterase 9A and can be used for the development of medicaments. Such medicaments shall preferably be used for the treatment of diseases in which the inhibition of PDE9A can evolve a therapeutic, prophylactic or disease modifying effect. Preferably the medicaments shall be used to improve perception, concentration, cognition, learning or memory, like those occurring in particular in situations/diseases/syndromes such as mild cognitive impairment, age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic dementia, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis.

Another aspect of the present invention concerns the treatment of a disease which is accessible by PDE9A modulation, in particular sleep disorders like insomnia or narcolepsy, bipolar disorder, metabolic syndrome, obesity, diabetes mellitus, including type 1 or type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, or a disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.

Thus the medical aspect of the present invention can be summarised in that it is considered that a compound according to formula (I), in particular the compounds of the embodiments as listed in the matrix I or a compound selected from the

- 60 -

compounds 1 through 47 as listed in table 1 is used as a medicament, preferably for humans.

Such a medicament preferably is for the treatment of a CNS disease.

5 In an alternative use, the medicament is for the treatment of a CNS disease, the treatment of which is accessible by the inhibition of PDE9.

In an alternative use, the medicament is for the treatment of a disease that is accessible by the inhibition of PDE9.

10 In an alternative use, the medicament is for the treatment, amelioration and / or prevention of cognitive impairment being related to perception, concentration, cognition, learning or memory.

15 In an alternative use, the medicament is for the treatment amelioration and / or prevention of cognitive impairment being related to age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic dementia, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS),
20 Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis.

In an alternative use, the medicament is for the treatment of Alzheimer's disease.

25 In an alternative use, the medicament is for the treatment of sleep disorders, bipolar disorder, metabolic syndrome, obesity, diabetes mellitus, hyperglycemia, dyslipidemia, impaired glucose tolerance, or a disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.

PHARMACEUTICAL COMPOSITIONS

- 61 -

Medicaments for administration comprise a compound according to the present invention in a therapeutically effective amount. By "therapeutically effective amount" it is meant that if the medicament is applied via the appropriate regimen adapted to the patient's condition, the amount of said compound of formula (I) will be sufficient to effectively treat, to prevent or to decelerate the progression of the corresponding disease, or otherwise to ameliorate the estate of a patient suffering from such a disease. It may be the case that the "therapeutically effective amount" in a monotherapy will differ from the "therapeutically effective amount" in a combination therapy with another medicament.

The dose range of the compounds of general formula (I) applicable per day is usually from 0.1 to 5000 mg, preferably 0.1 to 1000 mg, preferably from 2 to 500 mg, more preferably from 5 to 250 mg, most preferably from 10 to 100 mg. A dosage unit (e.g. a tablet) preferably contains between 2 and 250 mg, particularly preferably between 10 and 100 mg of the compounds according to the invention.

The actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age, weight, gender or other condition of the patient, route of administration, severity of disease, and the like.

The compounds according to the invention may be administered by oral, parenteral (intravenous, intramuscular etc.), intranasal, sublingual, inhalative, intrathecal, topical or rectal route. Suitable preparations for administering the compounds according to the present invention include for example patches, tablets, capsules, pills, pellets, dragees, powders, troches, suppositories, liquid preparations such as solutions, suspensions, emulsions, drops, syrups, elixirs, or gaseous preparations such as aerosols, sprays and the like. The content of the pharmaceutically active compound(s) should be in the range from 0.05 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as

- 62 -

magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

- 5 Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed
10 release, possibly using the excipients mentioned above for the tablets.

- Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange
15 extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

- Solutions are prepared in the usual way, e.g. with the addition of isotonic agents,
20 preservatives such as p-hydroxybenzoates or stabilisers such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as diluent, for example, organic solvents may optionally be used as solubilisers or dissolving aids, and the solutions may be transferred into injection vials or ampoules or infusion bottles.

- 25 Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.

- 30 Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.

- 63 -

Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).

- For oral use the tablets may obviously contain, in addition to the carriers specified, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gelatin and the like. Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to produce the tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.

The dosage of the compounds according to the invention is naturally highly dependent on the method of administration and the complaint which is being treated.

- When administered by inhalation the compounds of formula (I) are characterised by a high potency even at doses in the microgram range. The compounds of formula (I) may also be used effectively above the microgram range. The dosage may then be in the gram range, for example.

COMBINATIONS WITH OTHER ACTIVE SUBSTANCES

In another aspect the present invention relates to the above-mentioned pharmaceutical formulations as such which are characterised in that they contain a compound according to the present invention.

- A further aspect of the present invention refers to a combination of each of the compounds of the present invention, preferably at least one compound according to the present invention with another compound selected from the group of for example beta-secretase inhibitors; gamma-secretase inhibitors; gamma-secretase

- 64 -

modulators; amyloid aggregation inhibitors such as e.g. alzhemed; directly or indirectly acting neuroprotective substances, such as e.g. dimebon; directly or indirectly acting disease-modifying substances; anti-oxidants, such as e.g. vitamin E; ginko biloba or ginkgolide; anti-inflammatory substances, such as e.g. Cox inhibitors, NSAIDs additionally or exclusively having A β lowering properties; HMG-CoA reductase inhibitors such as statins; acetylcholine esterase inhibitors, such as donepezil, rivastigmine, tacrine, galantamine; NMDA receptor antagonists such as e.g. memantine; AMPA receptor agonists; AMPA receptor positive modulators, AMPKines; glycine transporter 1 inhibitors; monoamine receptor reuptake inhibitors; substances modulating the concentration or release of neurotransmitters; substances inducing the secretion of growth hormone such as ibutamoren mesylate and capromorelin; CB-1 receptor antagonists or inverse agonists; antibiotics such as minocyclin or rifampicin; PDE1, PDE2, PDE4, PDE5 and / or PDE10 inhibitors; GABAA receptor inverse agonists or GABAA receptor antagonists; nicotinic receptor agonists, partial agonists or positive modulators; alpha4beta2 nicotinic receptor agonists, partial agonists or positive modulators; alpha7 nicotinic receptor agonists, partial agonists or positive modulators; histamine receptor H3 antagonists; 5-HT4 receptor agonists, partial agonists or positive modulators; 5-HT6 receptor antagonists; alpha2-adrenoreceptor antagonists; calcium antagonists; muscarinic receptor M1 agonists, partial agonists or positive modulators; muscarinic receptor M2 antagonists; muscarinic receptor M4 antagonists; metabotropic glutamate receptor 5 positive modulators; metabotropic glutamate receptor 2 antagonists; and other substances that modulate receptors or enzymes in a manner such that the efficacy and/or safety of the compounds according to the invention is increased and/or unwanted side effects are reduced.

This invention further relates to pharmaceutical compositions containing one or more, preferably one active substance, which is selected from the compounds according to the invention and/or the corresponding salts, as well as one or more, preferably one active substance selected from among alzhemed, vitamin E, ginkgolide, donepezil, rivastigmine, tacrine, galantamine, memantine, ibutamoren mesylate, capromorelin, minocyclin and/or rifampicin, optionally together with one or more inert carriers and/or diluents.

The compounds according to the invention may also be used in combination with immunotherapies such as e.g. active immunisation with Abeta or parts thereof or passive immunisation with humanised anti-Abeta antibodies or antibody fragments
5 for the treatment of the above-mentioned diseases and conditions.

The combinations according to the present invention may be provided simultaneously in one and the same dosage form, i.e. in form of a combination preparation, for example the two components may be incorporated in one tablet, e. g. in different
10 layers of said tablet. The combination may be also provided separately, in form of a free combination, i.e the compounds of the present invention are provided in one dosage form and one or more of the above mentioned combination partners is provided in another dosage form. These two dosage forms may be equal dosage forms, for example a co-administration of two tablets, one containing a
15 therapeutically effective amount of the compound of the present invention and one containing a therapeutically effective amount of the above mentioned combination partner. It is also possible to combine different administration forms, if desired. Any type of suitable administration forms may be provided.

20 The compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may be used simultaneously or at staggered times, but particularly close together in time. If administered simultaneously, the two active substances are given to the patient together; if administered at staggered times the two active substances are given to the patient
25 successively within a period of less than or equal to 12, particularly less than or equal to 6 hours.

The dosage or administration forms are not limited, in the frame of the present invention any suitable dosage form may be used. Exemplarily the dosage forms may
30 be selected from solid preparations such as patches, tablets, capsules, pills, pellets, dragees, powders, troches, suppositories, liquid preparations such as solutions, suspensions, emulsions, drops, syrups, elixirs, or gaseous preparations such as aerosols, sprays and the like.

The dosage forms are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of each active component being present.

Depending from the administration route and dosage form the ingredients are
5 selected accordingly.

The dosage for the above-mentioned combination partners is expediently 1/5 of the normally recommended lowest dose up to 1/1 of the normally recommended dose.

10 The dosage forms are administered to the patient for example 1, 2, 3, or 4 times daily depending on the nature of the formulation. In case of retarding or extended release formulations or other pharmaceutical formulations, the same may be applied differently (e.g. once weekly or monthly etc.). It is preferred that the compounds of the invention be administered either three or fewer times, more preferably once or
15 twice daily.

EXAMPLES

PHARMACEUTICAL COMPOSITIONS

20 The following examples propose pharmaceutical formulations that may illustrate the present invention without restricting its scope:

The term "active substance" denotes one or more compounds according to the invention including the salts thereof.

Example A

Tablets containing 100 mg of active substance

30 Composition:

1 tablet contains:

active substance	100.0 mg
------------------	----------

- 67 -

	lactose	80.0 mg
	corn starch	34.0 mg
	polyvinylpyrrolidone	4.0 mg
	magnesium stearate	<u>2.0 mg</u>
5		220.0 mg

Example BTablets containing 150 mg of active substance

10

Composition:

1 tablet contains:

	active substance	150.0 mg
	powdered lactose	89.0 mg
15	corn starch	40.0 mg
	colloidal silica	10.0 mg
	polyvinylpyrrolidone	10.0 mg
	magnesium stearate	<u>1.0 mg</u>
		300.0 mg

20

Example CHard gelatine capsules containing 150 mg of active substance

25

1 capsule contains:

	active substance	150.0 mg
	corn starch (dried)	approx. 80.0 mg
	lactose (powdered)	approx. 87.0 mg
30	magnesium stearate	<u>3.0 mg</u>
		approx. 320.0 mg

- 68 -

Capsule shell: size 1 hard gelatine capsule.

Example D

5 Suppositories containing 150 mg of active substance

1 suppository contains:

	active substance	150.0 mg
	polyethyleneglycol 1500	550.0 mg
10	polyethyleneglycol 6000	460.0 mg
	polyoxyethylene sorbitan monostearate	<u>840.0 mg</u>
		2,000.0 mg

Example E

15

Ampoules containing 10 mg active substance

Composition:

	active substance	10.0 mg
20	0.01 N hydrochloric acid q.s.	
	double-distilled water	ad 2.0 mL

Example F

25

Ampoules containing 50 mg of active substance

Composition:

	active substance	50.0 mg
30	0.01 N hydrochloric acid q.s.	
	double-distilled water	ad 10.0 mL

The preparation of any the above mentioned formulations can be done following standard procedures.

5 BIOLOGICAL ASSAY

The in vitro effect of the compounds of the invention can be shown with the following biological assays.

PDE9A2 assay protocol:

- 10 The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (Amersham Biosciences, product number: TRKQ 7100).

- As enzyme source, lysate (PBS with 1% Triton X-100 supplemented with protease inhibitors, cell debris removed by centrifugation at 13.000 rpm for 30 min) of SF 9 cell
15 expressing the human PDE9A2 was used. The total protein amount included in the assay varied upon infection and production efficacy of the SF9 cells and lay in the range of 0.1 – 100 ng.

In general, the assay conditions were as follows:

- 20
- total assay volume: 40 microliter
 - protein amount: 0.1 – 50 ng
 - substrate concentration (cGMP): 20 nanomolar; ~1 mCi/l
 - incubation time: 60 min at room temperature
 - final DMSO concentration: 0.2 - 1%

25

- The assays were run in 384-well format. The test reagents as well as the enzyme and the substrate were diluted in assay buffer. The assay buffer contained 50 mM Tris, 8.3 mM MgCl₂, 1.7 mM EGTA, 0.1 % BSA, 0.05 % Tween 20; the pH of assay buffer was adjusted to 7.5. The reaction was stopped by applying a PDE9 specific
30 inhibitor (e.g. compounds according to WO04099210 or WO04099211) in excess.

Determination of % inhibition:

The activity of the positive control (minus the negative control = background) is set to 100% and activity in the presence of test compound is expressed relative to these 100%. Within this setting, an inhibition above 100% might be possible due to the nature of the variation of the positive control within the assay, however, in this case the reported % inhibition had been adjusted to 100%.

Determination of IC₅₀:

IC₅₀ can be calculated with GraphPadPrism or other suited software setting the positive control as 100 and the negative control as 0. For calculation of IC₅₀ dilutions of the test compounds (substrates) are to be selected and tested following the aforementioned protocol.

Data

In the following, % inhibition data will illustrate that the compounds according to the present invention are suited to inhibit PDE9 and thus provide useful pharmacological properties. The examples are not meant to be limiting. The table also provides IC₅₀ values. The values are presented as being within a nanomolar range (nM), i.e. within the range of either 1 nanomolar to 200 nanomolar or within the range of 201 nanomolar to 5000 nanomolar. The specific IC₅₀ value is within said range. The example number refer to the final examples as outlined in the section **Exemplary embodiments**.

All data are measured according to the procedure described herein.

Example No.	% inhibition of PDE9A2*	IC ₅₀ within range [nanomolar (nM)]	Example No.	% inhibition of PDE9A2	IC ₅₀ within range [nanomolar (nM)]
1	99	1-200	25	95	201-5000
2	100	1-200	26	99	1-200
3	100	1-200	27	98	1-200
4	97	1-200	28	94	1-200

Example No.	% inhibition of PDE9A2*	IC ₅₀ within range [nanomolar (nM)]	Example No.	% inhibition of PDE9A2	IC ₅₀ within range [nanomolar (nM)]
5	100	1-200	29	98	1-200
6	101	1-200	30	96	1-200
7	102	1-200	31	80	201-5000
8	100	1-200	32	91	1-200
9	100	1-200	33	83	201-5000
10	97	1-200	34	57	201-5000
11	94	1-200	35	50	201-5000
12	99	1-200	36	90	1-200
13	97	1-200	37	---	1-200
14	100	1-200	38	---	1-200
15	101	1-200	39	---	201-5000
16	98	1-200	40	---	201-5000
17	99	1-200	41	---	201-5000
18	96	1-200	42	---	201-5000
19	92	1-200	43	---	201-5000
20	71	201-5000	44	---	201-5000
21	66	1-200	45	---	201-5000
22	90	1-200	46	91	1-200
23	92	201-5000	47	89	201-5000
24	101	1-200			

* at 10 micromolar concentration

In vivo effect:

The in vivo effect of the compounds of this invention can be tested in the Novel Object Recognition test according to the procedure of Prickaerts *et al.*

5 (*Neuroscience*, **2002**, 113, 351-361).

For further information concerning biological testing of the compounds of the present invention see also *Neuropharmacology*, **2008**, 55, 908-918.

CHEMICAL MANUFACTURE

Abbreviations:

5		
	CDI	1,1'-carbonyldiimidazole
	DIPEA	diisopropylethylamine
	DME	1,2-dimethoxyethan
	DMF	dimethylformamide
10	ESI	electrospray ionization (in MS)
	Exp.	example
	h	hour(s)
	HATU	O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
15	HPLC	high performance liquid chromatography
	HPLC-MS	coupled high performance liquid chromatography-mass spectrometry
	M	molar (mol/L)
	min	minutes
	MS	mass spectrometry
20	NMP	1-methyl-2-pyrrolidinone
	R _t	retention time (in HPLC)
	TBTU	O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
25	TLC	thin-layer chromatography

LC-MS methods:30 **Method 1**

MS apparatus type: Waters Micromass ZQ; HPLC apparatus type: Waters Alliance 2695, Waters 2996 diode array detector; column: Varian Microsorb 100 C18, 30 x 4.6 mm, 3.0 μ m; eluent A: water + 0.13 % TFA, eluent B: acetonitrile; gradient: 0.0 min 5 % B \rightarrow 0.18 min 5 % B \rightarrow 2.0 min 98 % B \rightarrow 2.2 min 98 % B \rightarrow 2.3 min 5 % B \rightarrow 2.5 min 5 % B; flow rate: 3.5 mL/min; UV detection: 210-380 nm.

Method 2

MS apparatus type: Waters Micromass ZQ; HPLC apparatus type: Waters Alliance 2695, Waters 2996 diode array detector; column: Varian Microsorb 100 C18, 30 x 4.6 mm, 3.0 μ m; eluent A: water + 0.13 % TFA, eluent B: methanol; gradient: 0.0 min 5 % B \rightarrow 0.35 min 5 % B \rightarrow 3.95 min 100 % B \rightarrow 4.45 min 100 % B \rightarrow 4.55 min 5 % B \rightarrow 4.9 min 5 % B; flow rate: 2.4 mL/min; UV detection: 210-380 nm.

Microwave heating:


Microwave apparatus types:

- Discover® CEM instruments, equipped with 10 and 35 mL vessels;
- Biotage Initiator Sixty.


General comment concerning the presentation of the structures

Some compounds have one or more chiral centres. The depicted structure will not necessarily show all the possible stereochemical realisations of the compound but only one. However, in such cases a term like “cis-racemic mixture” is added next to the depicted structure in order to pin point to the other stereochemical options.


An example is given for Example 5A, below. The presented structural formula is

**trans - racemic mixture**

The added term “trans-racemic mixture” points to the second stereochemical option:



- 5 This principle applies to other depicted structures as well.

Starting compounds:**Example 1A**

10


5.00 g (37.3 mmol) 4,4-difluorocyclohexanone were mixed with 200 mL isopropanol and 5.30 g (40.1 mmol) t-butylcarbazate; 0.75 mL conc. acetic acid and PtO_2 were added. The reaction mixture was hydrogenated at room temperature (12h, 50 psi).

The reaction mixture was filtered and the solvent was evaporated under reduced pressure. 10 g (98 %) of the product were obtained.

MS (ESI pos): $m/z = 251$ ($M+H$)⁺

5

Example 2A




- 10 4.00 g (16.0 mmol) of Example 1A were mixed with 40 mL dichloromethane and 5.50 mL (71.4 mmol) trifluoroacetic acid were added. The reaction mixture was stirred 12h at room temperature. The solvent was evaporated under reduced pressure. 4.0 g (95 %) of the product were obtained.

MS (ESI pos): $m/z = 151$ ($M+H$)⁺

15

Example 3A



20


4.20 g (16.0 mmol) of Example 2A were suspended with 2.15 g (17.6 mmol) of ethoxymethylenemalononitrile in 50 mL of ethanol and 6.70 mL (48.0 mmol) of triethylamine were added. The reaction mixture was heated to 50°C for 2h. After

cooling to room temperature the solvent was removed under reduced pressure. The residue was suspended in dichloromethane. The suspension was filtered. 3.9 g (96 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.19$ min

5 MS (ESI pos): $m/z = 225$ (M-H)⁻

Example 4A



10


3.88 g (14.6 mmol) of Example 3A were mixed with 40 mL of ethanol. At room temperature a solution of 35 mL (0.41 mol) hydrogen peroxide (35 % in water) in 20 mL ammonia (25 % in water) was added over a period of 10 min. The reaction mixture was stirred at room temperature for 2h. The solution was concentrated to a volume of 50 mL under reduced pressure. The residue was mixed with

15 dichloromethane and water. The organic layer was extracted with water and 40 % $\text{Na}_2\text{S}_2\text{O}_3$ solution. The organic layer was dried, filtered and the filtrate was concentrated under reduced pressure. 2.44 g (68 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 0.91$ min

20 MS (ESI pos): $m/z = 245$ (M+H)⁺

Example 5A (trans – racemic mixture)

**trans - racemic mixture**


2.00 g (13.9 mmol) trans-cyclobutan-1,2-dicarboxylic acid were mixed with 16 mL ethanol at 0°C and 2.21 mL (30.5 mmol) thionylchloride were slowly added. The mixture was allowed to warm to room temperature and stirred for 1 hour. The solvent was removed under reduced pressure and the product was filtered through a pad of activated basic alumina. 2.71 g (98 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.34$ min

MS (ESI pos): $m/z = 201$ (M+H)⁺


- 10 The following examples were synthesized in analogy to the preparation of Example 5A, using the corresponding dicarboxylic acids as starting materials:

Example	structure	starting material	R_t [min]	MS (ESI pos, m/z)
Exp. 5B cis – racemic mixture			1.39 (Method 1)	215 (M+H) ⁺
Exp. 5C trans – racemic mixture			1.55 (Method 1)	229 (M+H) ⁺

Example 6A (trans – racemic mixture)**trans - racemic mixture**

- 5 100 mg (0.30 mmol) of Example 33 were mixed with 1 mL of dichloromethane and 60 μ L (0.44 mmol) 2,4,6-collidine at 0°C. A solution of 30 μ L (0.38 mmol) of methanesulfonylchloride in 1 mL of dichloromethane was added dropwise. The reaction mixture was heated to room temperature and stirred for 2h. Saturated sodium hydrogen carbonate solution was added and the phases were separated.
- 10 The organic layer was dried and the solvent was removed under reduced pressure. 121 mg (98 %) of the product were obtained. The material was used for the next reaction without further purification.
- HPLC-MS (Method 1): $R_t = 1.37$ min
MS (ESI pos): $m/z = 417$ ($M+H$)⁺

15

Example 7A (trans – racemic mixture)**trans - racemic mixture**


150 mg (0.61 mmol) of Example 4A were mixed with 2 mL of absolute ethanol, 395 mg (1.84 mmol) of Example 5B and 118 mg (2.95 mmol) of sodium hydride (60 % suspension in mineral oil) were added. The reaction mixture was heated to 140°C for 30 min in a microwave oven. The mixture was cooled to room temperature and sodium hydroxide solution (4 M in water) was added. The solvent was removed under reduced pressure. The substance was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 109 mg (48 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.29$ min

MS (ESI pos): $m/z = 367$ ($M+H$)⁺

The following examples were synthesized in analogy to the preparation of Example 7A, using the corresponding dicarboxylic esters as starting materials:

Example	structure	starting material	R_t [min]	MS (ESI pos, m/z)
Exp. 7B trans – racemic mixture			1.22 (Method 1)	339 ($M+H$) ⁺
Exp. 7C trans – racemic mixture		Exp. 5C	1.31 (Method 1)	381 ($M+H$) ⁺


Example 8A (trans – racemic mixture)

300 mg (1.74 mmol) trans-cyclopentane-1,2-dicarboxylic acid monomethyl ester were
5 mixed with 2 mL DMF and 0.30 mL (1.74 mmol) DIPEA. 615 mg (1.92 mmol) TBTU
was added and stirred for 10 minutes at room temperature. 300 μ L (1.74 mmol)
DIPEA and 290 μ L piperidine were added and stirred at room temperature for 1 h.
The reaction mixture was evaporated under reduced pressure. The residue was
purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile).
10 400 mg (96 %) of the product were obtained.

HPLC-MS (Method 1): R_t = 1.26 min

MS (ESI pos): m/z = 240 ($M+H$)⁺

15 Example 9A (trans – racemic mixture)

**trans - racemic mixture**


0.20 g (1.03 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxylic acid amide
(DE 10238724) were mixed with 2 mL of absolute ethanol, 0.62 g (3.09 mmol) of
20 Example 5A, and 0.16 g (4.12 mmol) of sodium hydride (60 % suspension in mineral
oil) were added. The reaction mixture was heated to 140°C for 30 min in a microwave
oven. The mixture was cooled to room temperature and the solvent was evaporated

under reduced pressure. The substance was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 87 mg (26 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.49$ min

5 MS (ESI pos): $m/z = 331$ ($M+H$)⁺

Example 10A (trans – racemic mixture)



trans - racemic mixture

10

65 mg (0.20 mmol) of Example 9A were mixed with 3 mL methylene chloride and 10 mL sodium hydroxide solution (4 M in water) were added. The mixture was stirred at room temperature for 1 h. The mixture was acidified with hydrochloric acid and extracted with ethyl acetate. The combined organic layers were dried and evaporated under reduced pressure. 57.0 mg (96 %) of the product were obtained.


15

HPLC-MS (Method 1): $R_t = 1.23$ min

MS (ESI pos): $m/z = 303$ ($M+H$)⁺


The following example was synthesized in analogy to the preparation of Example 10A, using the corresponding esters as starting materials:

Example	structure	starting material

<p>Exp. 10B</p> <p>mixture of stereoisomers</p>		<p>Exp. 14A</p>
---	---	-----------------

Example 11A (cis – racemic mixture)

5




cis - racemic mixture

110 mg (0.52 mmol) of cis-2-(piperidine-1-carbonyl)-cyclobutanecarboxylic acid (P. Schenone et al., Il Farmaco, Ed. Sc.; 27, 1972, 200-207) were mixed with 1 mL

10 chloroform. 0.08 mL (1.15 mmol) of thionyl chloride were added. The reaction mixture was stirred at reflux for 2 h. The reaction mixture was evaporated under reduced pressure. The residue was used for the next step without further purification.

Example 12A (cis – racemic mixture)

15




cis - racemic mixture

50.0 mg (0.20 mmol) of Example 4A and 119 mg (0.52 mmol) of Example 11A were mixed with 2 mL of NMP were stirred over night at room temperature. The reaction mixture was diluted with water and purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 33 mg (37 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.21$ min

MS (ESI neg): $m/z = 436$ (M-H)⁻

Example 13A





1.25 g (9.75 mmol) 3,3-Dimethylcyclobutanecarboxylic acid were dissolved in 10 mL acetonitrile/methanol (9/1). 6.34 mL Trimethylsilyldiazomethane (2M solution in diethylether) were added. Some drops of acetic acid were added. The reaction mixture was concentrated under reduced pressure. 1.30 g (94 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.50$ min


MS (ESI neg): $m/z = 143 (M+H)^+$

The following example was synthesized in analogy to the preparation of Example 13A, using the corresponding dicarboxylic esters as starting materials:

Example	structure	starting material	R_t [min]	MS (ESI pos/neg, m/z)
Exp. 13B			1.08 (Method 1)	113 (M-H) ⁻

5

Example 14A mixture of stereoisomers



mixture of stereoisomers

1.00 g (5.10 mmol) of 5-amino-1-(1-ethylpropyl)-1H-pyrazole-4-carboxamide (DE 10238722) was mixed with 3 mL of absolute ethanol, 4.59 g (22.9 mmol) of cyclohexane-1,4-dicarboxylic acid dimethyl ester, and 1.73 g (25.4 mmol) of sodium ethylate were added. The reaction mixture was heated to 78°C for 12h. The mixture was cooled to room temperature. Water was added and the mixture was extracted with ethyl acetate. The solvent was removed under reduced pressure. The substance was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 0.60 g (34 %) of the product were obtained.

10


15

HPLC-MS : Identity and purity confirmed

NMR: Identity confirmed

Exemplary embodiments

5 Example 1 (trans – racemic mixture)











trans - racemic mixture





- 50.0 mg (0.14 mmol) of Example 46 were mixed with 2 mL DMF and 25 μ L (0.14 mmol) DIPEA. 59.6 mg (0.16 mmol) HATU were added and stirred for 10 minutes at room temperature. 75 μ L (0.43 mmol) DIPEA and 24.6 μ L (0.28 mmol) morpholine were added and stirred at room temperature for 1 h. The reaction mixture was evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 38.7 mg (60 %) of the product were obtained.
- 15 HPLC-MS (Method 1): R_t = 1.21 min
MS (ESI pos): m/z = 422 ($M+H$)⁺







The following examples were synthesized in analogy to the preparation of Example 1, using the corresponding pyrazoles and amines as starting materials





Example	structure	starting material: pyrazole	starting material: amine	R_t [min]	MS (ESI pos, m/z)





<p>Exp. 2</p> <p>diastereo- meric mixture; trans config- uration at the cyclo- butane ring; stereocentre at pyrrolidine is “R” for both diastereo- mers</p>		<p>Exp. 46</p>		<p>1.30 (Method 1)</p>	<p>424 (M+H)⁺</p>
<p>Exp. 3</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>		<p>1.34 (Method 1)</p>	<p>442 (M+H)⁺</p>





<p>Exp. 4</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>HCl</p>	<p>1.42 (Method 1)</p>	<p>478 (M+H)⁺</p>
<p>Exp. 5</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>H. Najer et al., Bull. Soc. Chim. Fr., 1965; 2118</p>	<p>1.46 (Method 1)</p>	<p>432 (M+H)⁺</p>





<p>Exp. 6</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>HCl</p>	<p>1.52 (Method 1)</p>	<p>488 (M+H)⁺</p>
<p>Exp. 7</p> <p>diastereo- meric mixture; trans configuratio n at the cyclobutane ring; stereo- centre at pyrrolidine is “R” for both diastereo- mers</p>		<p>Exp. 46</p>	 <p>ClH</p> <p>WO 2005- 49616</p>	<p>1.29 (Method 1)</p>	<p>436 (M+H)⁺</p>







Exp. 8 diastereo- meric mixture; trans configuratio n at the cyclobutane ring		Exp. 46	 3B Scientific Corp., Libertyville, USA	1.48 (Method 1)	446 (M+H) ⁺
Exp. 9 trans – racemic mixture		Exp. 46	 HCl	1.44 (Method 1)	456 (M+H) ⁺
Exp. 10 trans – racemic mixture		Exp. 46		1.57 (Method 1)	448 (M+H) ⁺



<p>Exp. 11</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>ClH</p>	<p>1.33 (Method 1)</p>	<p>438 (M+H)⁺</p>
<p>Exp. 12</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>NH</p>	<p>1.32 (Method 1)</p>	<p>406 (M+H)⁺</p>


<p>Exp. 13</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>McManus, J.M. et al., J. Med. Chem., 8, 1965; 766- 776</p>	<p>1.39 (Method 1)</p>	<p>464 (M+H)⁺</p>
<p>Exp. 14</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>HCl</p>	<p>1.38 (Method 1)</p>	<p>456 (M+H)⁺</p>

<p>Exp. 15</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>		<p>1.49 (Method 1)</p>	<p>434 (M+H)⁺</p>
<p>Exp. 16</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>	 <p>ClH</p> <p>WO 2006- 66174</p>	<p>1.33 (Method 1)</p>	<p>450 (M+H)⁺</p>

<p>Exp. 17</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>		<p>1.38 (Method 1)</p>	<p>408 (M+H)⁺</p>
<p>Exp. 18</p> <p>trans – racemic mixture</p>		<p>Exp. 46</p>		<p>1.47 (Method 1)</p>	<p>420 (M+H)⁺</p>



Exp. 19 trans – racemic mixture		Exp. 7A		1.46 (Method 1)	470 (M+H) ⁺
Exp. 20 trans – racemic mixture		Exp. 7C		1.32 (Method 1)	450 (M+H) ⁺
Exp. 21 trans – racemic mixture		Exp. 7C		1.42 (Method 1)	434 (M+H) ⁺


Exp. 22 trans – racemic mixture		Exp. 46		2.75 (Method 2)	390 (M+H) ⁺
--	---	------------	--	-----------------------	---------------------------

Example 23 (trans – racemic mixture)**trans - racemic mixture**

- 5 70 mg (0.21 mmol) of Example 7B were mixed with 1 mL DMF and 35 μ L (0.21 mmol) DIPEA. 73 mg (0.23 mmol) TBTU were added and stirred for 10 minutes at room temperature. 35 μ L (0.21 mmol) DIPEA and 30 μ L piperidine were added and stirred at room temperature for 1 h. The reaction mixture was evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water +
- 10 0.13 % TFA, eluent B: acetonitrile). 59 mg (70 %) of the product were obtained.
HPLC-MS (Method 1): R_t = 1.39 min
MS (ESI pos): m/z = 406 (M+H)⁺

The following example was synthesized in analogy to the preparation of Example 23:

Example	structure	starting material 1	starting material 2	R _t [min]	MS (ESI pos, m/z)
Exp. 24 trans – racemic mixture		Exp.10A		1.50 (Method 1)	370 (M+H) ⁺


Example 25 (trans – racemic mixture)**trans - racemic mixture**

100 mg (0.41 mmol) of Example 4A were mixed with 2 mL of absolute ethanol, 220 mg (0.96 mmol) of Example 8A, and 66.0 mg (1.64 mmol) of sodium hydride (60 % suspension in mineral oil) were added. The reaction mixture was heated to 140°C for 30 min in a microwave oven. The mixture was cooled to room temperature. The solvent was removed under reduced pressure. The substance was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 12 mg (7 %) of the product were obtained.


HPLC-MS (Method 1): R_t = 1.47 min

MS (ESI pos): m/z = 434 (M+H)⁺

The following example was synthesized in analogy to the preparation of Example 25:

Example	structure	starting material 1	starting material 2	R _t [min]	MS (ESI pos, m/z)
Exp. 26 trans – racemic mixture		5-Amino-1-cyclopentyl-1H-pyrazole-4-carboxylic acid amide (DE 10238724)	Exp.8A	1.50 (Method 1)	384 (M+H) ⁺

5 Example 27 (trans – racemic mixture)



trans - racemic mixture

- 0.20 g (1.03 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxylic acid amide (DE 10238724) were mixed with 2 mL of absolute ethanol, 0.62 g (3.09 mmol) of Example 5A, and 0.16 g (4.12 mmol) of sodium hydride (60 % suspension in mineral oil) were added. The reaction mixture was heated to 140°C for 30 min in a microwave oven. The mixture was cooled to room temperature and the solvent was evaporated under reduced pressure. The substance was purified by preparative HPLC (eluent A:


water + 0.13 % TFA, eluent B: acetonitrile). 87.0 mg (26 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.49$ min

MS (ESI pos): $m/z = 331$ ($M+H$)⁺

5

Example 28 (trans – racemic mixture)




trans - racemic mixture

77.0 mg (0.16 mmol) of Example 4 were mixed with THF and 0.10 mL LiAlH₄ (2 M solution in THF) were added. After stirring for 30 min at reflux, the mixture was quenched with water/THF and then evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 33 mg (44 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.59$ min

MS (ESI pos): $m/z = 464$ ($M+H$)⁺

Example 29




50.0 mg (0.26 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxylic acid amide (DE 10238724) and 41.8 mg (0.51 mmol) cyclobutanecarbonitrile were mixed with 2 mL ethanol. 30.9 mg (1.29 mmol) sodium hydride (60 % suspension in mineral oil) were added. The mixture was heated to 150°C for 30 min in a microwave oven. The substance was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 5 mg (7.5 %) of the product were obtained.


HPLC-MS (Method 1): $R_t = 1.38$ min

10 MS (ESI pos): $m/z = 259$ ($M+H$)⁺

The following example was synthesized in analogy to the preparation of Example 29:

Example	structure	starting material 1	starting material 2	R_t [min]	MS (ESI pos, m/z)
Exp. 30		Exp. 4A	cyclobutane-carbonitrile	1.43 (Method 1)	309 ($M+H$) ⁺

Exp. 31		5-amino-1-(4-methylpyridin-3-yl)-1H-pyrazole-4-carboxylic acid amide (WO 2004/099211)	cyclobutane-carbonitrile	0.90 (Method 1)	282 (M+H) ⁺
---------	---	--	--------------------------	--------------------	---------------------------


Example 32 (trans – racemic mixture)**trans - racemic mixture**

- 5 200 mg (0.57 mmol) of Example 46 were mixed with 1 mL DMF and 92.0 mg (0.57 mmol) of CDI were added. After stirring at room temperature for 6 h, 42.1 mg (0.57 mmol) of *N*-hydroxyacetamidine were added. After stirring for 2 h at room temperature the mixture was heated to 100°C and stirred 16 h. The mixture was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile).
- 10 160 mg (72 %) of the product were obtained.

HPLC-MS (Method 1): R_t = 1.38 min

MS (ESI pos): m/z = 391 (M+H)⁺

15 Example 33 (trans – racemic mixture)

**trans - racemic mixture**


600 mg (1.70 mmol) of Example 46 were mixed with 10 mL DME and cooled to -22°C. 0.28 mL (2.55 mmol) of *N*-methylmorpholine and a solution of 0.29 mL (2.21 mmol) isobutyl chloroformate in DME were added. The mixture was warmed up to -5°C and filtered. The filtrate was cooled to -15°C and 122 mg (3.24 mmol) of sodium borohydride and two drops of water were added. The mixture was warmed to room temperature and stirred for 30 min. The solvent was evaporated under reduced pressure. The residue was extracted with ethyl acetate. The combined organic layers were dried and evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 480 mg (83 %) of the product were obtained.

HPLC-MS (Method 1): $R_t = 1.28$ min

MS (ESI pos): $m/z = 339$ ($M+H$)⁺


15

Example 34 (cis – racemic mixture)

**cis - racemic mixture**

33.3 mg (0.08 mmol) of Example 12A and 49.6 mg (0.15 mmol) of cesium carbonate were mixed with 1 mL of methanol. The reaction mixture was heated to 100°C for 30 min in a microwave oven. The mixture was cooled to room temperature. The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 8 mg (25 %) of the title compound were obtained as earlier eluting stereoisomer. Minor amounts of the later eluting stereoisomer Example 18 were collected separately.

10 HPLC-MS (Method 1): $R_t = 1.32$ min
MS (ESI pos): $m/z = 420$ (M+H)⁺

Example 35

15


100 mg (0.46 mmol) of 5-amino-1-(4-methyl-pyridin-3-yl)-1H-pyrazole-4-carboxylic acid amide (WO 2004/099211) and 262 mg (1.84 mmol) Example 13A were mixed with 3 mL of ethanol. 55.2 mg (2.30 mmol) sodium hydride (60 % suspension in mineral oil) was added. The reaction mixture was heated to 150°C for 30 min in a

microwave oven. The residue was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 28 mg (20 %) of the product were obtained.


HPLC-MS (Methode 1): $R_t = 1.10$ min

5 MS (ESI pos): $m/z = 310$ ($M+H$)⁺

The following example was synthesized in analogy to the preparation of Example 35:

Example	structure	starting material 1	starting material 2	R_t [min]	MS (ESI pos, m/z)
Exp. 36 trans – racemic mixture		5-amino-1-(4-methyl-pyridin-3-yl)-1H-pyrazole-4-carboxylic acid amide (WO 2004/099211)	Exp. 13B	0.91 (Method 1)	282 ($M+H$) ⁺





Example 37 (mixture of stereoisomers)











100 mg (0.46 mmol) of 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxamide (WO 2004/099210), 267 mg (20.8 mmol) of ethyl 2-methylcyclopropane-1-carboxylate and 157 mg (23.1 mmol) of sodium ethoxide were mixed with 25 mL ethanol and stirred at reflux overnight. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were dried and evaporated under reduced pressure. The residue was purified by flash chromatography. 46.2 mg (36 %) of the product were obtained.

HPLC-MS: Identity and purity confirmed.

The following examples were synthesized in analogy to the preparation of Example 37:


Example	structure	starting material 1	starting material 2	
Exp. 38 mixture of stereo- isomers		5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxamide WO 2004/099210	 3B Scientific Corp., Libertyville, USA	Identity and purity confirmed by HPLC-MS
Exp. 39 mixture of stereo- isomers		5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxamide WO 2004/099210		Identity and purity confirmed by HPLC-MS

Exp. 40 mixture of stereo- isomers		5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxamide WO 2004/099210	 H. Ungnade <i>et al.</i> , J. Am. Chem. Soc., Vol. 70, 1948, 1898	Identity and purity confirmed by HPLC-MS and NMR
Exp. 41 mixture of stereo- isomers		5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxamide WO 2004/099210	 *	Identity and purity confirmed by HPLC-MS and NMR
Exp. 42 mixture of stereo- isomers		5-amino-1-(1-ethylpropyl)-1H-pyrazole-4-carboxamide (DE 10238722),	 3B Scientific Corp., Libertyville, USA	Identity and purity confirmed by HPLC-MS

Exp. 43 trans – enantio- meric mixture		5-amino-1-(1-ethylpropyl)-1H-pyrazole-4-carboxamide (DE 10238722),		Identity and purity confirmed by HPLC-MS
--	---	---	---	---

* 2-Oxo-hexahydro-benzo[1,3]dioxole-5-carboxylic acid methyl ester can be synthesized from the corresponding diol by various methods, e.g. with carbonic acid ditrichloromethyl ester (R.M. Burk et. al., Tetrahedron Lett., 34, 1993, 395-398).

5 Example 44 mixture of stereoisomers




100 mg (0.30 mmol) of Example 10B, 46.1 mg (0.30 mmol) of 3,5-dimethoxyaniline, 289 mg (0.60 mmol) of HATU and 77.8 mg (0.60 mmol) of DIPEA were mixed with
10 DMF and stirred overnight at room temperature. The reaction mixture was purified by preparative chromatography. 90.0 mg (64 %) of the product were obtained.

HPLC-MS : Identity and purity confirmed

NMR: Identity confirmed

15


Example 45 (racemic mixture, earlier eluting diastereomer)



200 mg (0.56 mmol) of Example 41 and 162 mg (2.89 mmol) of potassium hydroxide were mixed with 10 mL ethanol and 1 mL water. The mixture was stirred for 12h and the solvent was evaporated under reduced pressure. The residue was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 40 mg (20 %) of the product were obtained as the earlier eluting diastereomer.

HPLC-MS : Identity and purity confirmed

Example 46 (trans – racemic mixture)




1.00 g (4.09 mmol) of Example 4A was mixed with 15 mL of absolute ethanol, 2.46 g (12.28 mmol) of Example 5A and 0.66 g (16.4 mmol) of sodium hydride (60 % suspension in mineral oil) were added. The reaction mixture was heated to 140°C for 30 min in a microwave oven. The mixture was cooled to room temperature and sodium hydroxide solution (4 M in water) was added. The solvent was removed under reduced pressure. The substance was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). 0.70 g (49 %) of the product were obtained.

HPLC-MS (Method 1): R_t = 1.24 min

MS (ESI pos): $m/z = 353 (M+H)^+$

Example 47 (trans – racemic mixture)




- 5 39 mg (0.58 mmol) pyrazole were mixed with 1.0 mL DMF and 19.6 mg (0.49 mmol) of sodium hydride (60 % suspension in mineral oil) were added. 121 mg (0.29 mmol) of Example 6A dissolved in 1.0 mL DMF was added. The mixture was stirred for 12h at room temperature. Dichloromethane and water were added. The organic phase was separated and the solvent was removed under reduced pressure. The residue
- 10 was purified by preparative HPLC (eluent A: water + 0.13 % TFA, eluent B: acetonitrile). The obtained material was dissolved in dichloromethane, acidified with saturated HCl in isopropanol and evaporated to dryness to obtain 5.0 mg (4 %) of the product as hydrochloride salt.

HPLC-MS (Method 1): $R_t = 1.38$ min

- 15 MS (ESI pos): $m/z = 389 (M+H)^+$

Claims

1. A compound of formula (I)



5 wherein

R^1 is selected independently for each R^1 from the group R^{1a} consisting of Hydrogen, fluorine, chlorine, bromine, $NC-$, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, heterocyclyl-CO-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ -, $R^{10}O$ -CO-, $(R^9)_2N$ -CO-, R^{10} -CO- $(R^{10})N$ -, R^{10} -CO-, $(R^9)_2N$ -CO- $(R^{10})N$ -, $(R^9)_2N$ -CO-O-, R^{10} -O-CO- $(R^{10})N$ -, R^{10} -SO₂- $(R^{10})N$ -, and C_{1-6} -alkyl-SO₂-,

where the above-mentioned members HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, R^{10} -O- C_{1-3} -alkyl-, heterocyclyl-CO-, and C_{1-6} -alkyl-SO₂- may optionally be substituted independently of one

another by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine, bromine, OH-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, (R¹⁰)₂N-CO-, C₃₋₆-cycloalkyl-, C₃₋₆-cycloalkyl-C₁₋₄-alkyl-, and C₁₋₆-alkyl-, preferably from the group consisting of fluorine, chlorine, bromine, OH-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, (R¹⁰)₂N-CO-, C₃₋₆-cycloalkyl-, and C₃₋₆-cycloalkyl-C₁₋₄-alkyl-,

L is selected from the integers 0, 1, 2 and 3,

x is selected from the integers 0, 1, 2, 3 and 4,

y is selected from the integers 0, 1 and 2,

D is selected from the group D^{1a} consisting of heterocyclyl,

wherein the above-mentioned members of the group D^{1a} may optionally be substituted by one or more substituents selected independently of one another from the group R² and/or optionally substituted by one group R³

5 or

D is selected from the group D^{2a} consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl cyclooctyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctatrienyl and cyclooctatetraenyl,

wherein the above-mentioned members of the group D^{2a} may optionally be substituted by one or more substituents selected independently of one another from the group R⁴,

or

D is selected from the group D^{3a} consisting of C₁₋₈-alkyl

wherein the above-mentioned C₁₋₈-alkyl-group D^{3a} may optionally be

substituted by one or more substituents selected independently of one another from the group R⁵.

or

D is selected from the group D^{4a} consisting of aryl wherein the above-mentioned aryl group D^{4a} may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R⁶. Preferred are such compounds wherein D^{4a} is substituted by not more than one R⁶.

or

D is selected from the group D^{5a} consisting of heteroaryl wherein the above-mentioned members of the group D^{5a} may optionally be substituted by one or more substituents selected independently of one another from the group R⁶. Preferred are such compounds wherein D^{5a} is substituted by not more than one R⁶.

R² is selected from the group R^{2a} consisting of H-, fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, carboxy-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₂₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R¹⁰)₂N-CO-(R¹⁰)N-, R¹⁰-O-CO-(R¹⁰)N-, R¹⁰-SO₂-(R¹⁰)N-, C₁₋₆-alkyl-SO₂-, and oxo,

where the above-mentioned members HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl- (preferably C₂₋₆-alkyl), C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋

₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₂₋₃-alkyl-, (R¹⁰)₂N-C₁₋₃-alkyl-, and C₁₋₆-alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of

fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

and in cases in that D¹ is a heterocyclyl group with NR² as ring member, R² shall be

independently of any other R²: H-, F₃C-CH₂-, HF₂C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-, R¹⁰-SO₂-, and C₁₋₆-alkyl-SO₂-,

where the above-mentioned members F₃C-CH₂-, HF₂C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₃-alkyl-, and C₁₋₆-alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of

fluorine, HO-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, R¹⁰-O-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

R^3 is selected from the group R^{3a} consisting of
H-, HO- and R^{10} -O-,

R^4 is selected from the group R^{4a} consisting of
H-, fluorine, chlorine, bromine, HO-, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -,
carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S-
 C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -
alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl-
 C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-,
aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl-,
heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl - C_{2-6} -alkynyl-,
 R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $R^{10}O-CO$ -, $(R^{10})_2N$ -
 CO -, $R^{10}-CO-(R^{10})N$ -, $R^{10}-CO$ -, $(R^{10})_2N-CO-(R^{10})N$ -, $R^{10}-O-CO-(R^{10})N$ -,
 $R^{10}-SO_2-(R^{10})N$ -, and C_{1-6} -alkyl- SO_2 -,

where the above-mentioned members HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl-,
 C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -
cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -
alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-
 C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -
alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heteroaryl -
 C_{2-6} -alkenyl-, heteroaryl - C_{2-6} -alkynyl-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ - C_{1-3} -alkyl-,
and C_{1-6} -alkyl- SO_2 - may optionally be substituted independently of one
another by one or more substituents selected from the group consisting of
fluorine, chlorine, bromine, NC-, O_2N -, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, HO-
 C_{1-6} -alkyl-, C_{1-6} -alkyl-O-, C_{1-6} -alkyl-O- C_{1-6} -alkyl-, C_{1-6} -alkyl-, $(R^{10})_2N$ -,
 $(R^{10})_2N$ - C_{1-3} -alkyl-, and $(R^{10})_2N-CO$ -,

or

two substituents R^{4a} together form a C_{2-6} -alkylene bridge, wherein one or
two CH_2 groups of the C_{2-6} -alkylene bridge may be replaced independently
of one another by O, S, SO, SO_2 , $N(R^{10})$ or $N-C(O)-R^{10}$ in such a way that
in each case two O or S atoms or an O and an S atom are not joined

together directly.

R^5 is selected from the group R^{5a} consisting of H-, fluorine, chlorine, bromine, HO-, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $R^{10}O-CO$ -, $(R^{10})_2N-CO$ -, $R^{10}-CO-(R^{10})N$ -, $R^{10}-CO$ -, $(R^{10})_2N-CO-(R^{10})N$ -, $R^{10}-O-CO-(R^{10})N$ -, $R^{10}-SO_2-(R^{10})N$ -, and C_{1-6} -alkyl- SO_2 -,

where the above-mentioned members HF_2C -, FH_2C -, F_3C-CH_2 -, carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkenyl-, C_{3-7} -cycloalkyl- C_{2-6} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkenyl-, C_{3-7} -heterocyclyl- C_{2-6} -alkynyl-, aryl, aryl- C_{1-6} -alkyl-, aryl- C_{2-6} -alkenyl-, aryl- C_{2-6} -alkynyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heteroaryl- C_{2-6} -alkenyl-, heteroaryl- C_{2-6} -alkynyl-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N$ - C_{1-3} -alkyl-, and C_{1-6} -alkyl- SO_2 -, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O_2N -, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, HO- C_{1-6} -alkyl-, C_{1-6} -alkyl-O-, C_{1-6} -alkyl-O- C_{1-6} -alkyl-, C_{1-6} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, and $(R^{10})_2N-CO$ -,

R^6 is selected from the group R^{6a} consisting of H-, fluorine, chlorine, bromine, HO-, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, carboxy-, C_{1-6} -alkyl-, C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -cycloalkyl- C_{2-6} -

alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R¹⁰)₂N-CO-(R¹⁰)N-, R¹⁰-O-CO-(R¹⁰)N-, R¹⁰-SO₂-(R¹⁰)N-, and C₁₋₆-alkyl-SO₂-,

where the above-mentioned members HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₂₋₆-alkynyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-C₂₋₆-alkynyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkenyl-, C₃₋₇-heterocyclyl-C₂₋₆-alkynyl-, aryl, aryl-C₁₋₆-alkyl-, aryl-C₂₋₆-alkenyl-, aryl-C₂₋₆-alkynyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, heteroaryl-C₂₋₆-alkenyl-, heteroaryl-C₂₋₆-alkynyl-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-C₁₋₃-alkyl- and C₁₋₆-alkyl-SO₂- may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

R⁹ is selected independently for each R⁹ from the group R^{9a} consisting of H-, F₃C-CH₂-, C₂₋₆-alkenyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, heteroaryl-C₁₋₃-alkyl- and C₁₋₆-alkyl-, and where the above-mentioned members F₃C-CH₂-, C₂₋₆-alkenyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, heteroaryl-C₁₋₃-alkyl- and C₁₋₆-alkyl-, may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine, bromine, HO-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-,

HO-C₁₋₆-alkyl-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-O- and C₁₋₆-alkyl-,


R¹⁰ is selected independently for each R¹⁰ from the group R^{10a} consisting of H- (but not in case is part of a group being selected from R¹⁰O-CO-, R¹⁰-SO₂- or R¹⁰-CO-), F₃C-CH₂-, C₁₋₆-alkyl-, C₂₋₆-alkenyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, and heteroaryl-C₁₋₃-alkyl-, and in case where two R¹⁰ groups both are bound to the same nitrogen atom they may together with said nitrogen atom form a 3 to 12 membered heterocyclyl ring, and wherein one of the -CH₂-groups of the heterocyclic ring formed may be replaced by -O-, -S-, -NH-, -N(C₃₋₆-cycloalkyl)-, -N(C₃₋₆-cycloalkyl-C₁₋₄-alkyl)- or -N(C₁₋₄-alkyl)- and where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO-, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl- and C₁₋₆-alkyl-O-,

and pharmaceutically acceptable salts thereof.

5 2. A compound according to claim 1, wherein

D is selected from the group D^{1b} consisting of heterocyclyl, defined by any of formulas I.1 or I.2 or I.3:

formula I.1:



with


$n = 1, 2, 3$;

meaning that the ring is not aromatic while for $n = 1$, one bond within the ring system optionally may be a double bond and for $n = 2$ or 3 one bond or two bonds within the ring system optionally may be (a) double bond(s). For each occasion the double bond preferably is a C-C double bond. Preferably the ring system is saturated,

X^1, X^2, X^3 , independently from each other being CH_2 , CHR^2 , CHR^3 , $C(R^2)_2$, CR^2R^3 , O, NH, NR^2 , or $S(O)_r$ with $r = 0, 1, 2$, whereby at least one of X^1, X^2, X^3 is O, NH, NR^2 or $S(O)_r$, whereby the substituents R^2 and R^3 are selected independently of each other;

The * represents the point of attachment to the nitrogen atom of the pyrazolo ring of formula I;

formula I.2:




with

A being the ring system of formula I.1;

B being a 3, 4, 5 or 6 membered second ring systems that is anellated to A and that beside the two atoms and one bond it shares with A consists only of carbon atoms and that may be saturated, partially saturated or aromatic, the ring system of formula I.2 may optionally be substituted by one or more substituents selected independently of one another from the group R^2 and/or optionally substituted by one group R^3 and whereby the two ring atoms that are shared by the two ring systems A and B both may be C-atoms, both may be N-atoms or one may be a C- and the other one may be a N-atom. Preferred are two C-atoms, or one C- and one N-atom, and more preferred are two C-atoms. The shared bond may be a single bond or a double bond;

formula I.3:



with

A, being the ring system of formula I.1;

C being a 3, 4, 5 or 6 membered second ring systems that is spiro fused to **A** and that beside the one atoms it shares with **A** consists only of carbon atoms and that may be saturated, partially saturated or aromatic whereby the ring system of formula I.3 may optionally be substituted by one or more substituents selected independently of one another from the group R^2 and/or optionally substituted by one group R^3 and whereby the ring atom that is shared by the two ring systems **A** and **C** is a C-atom,

or

D is selected from the group D^{2b} consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl and cyclohexenyl, wherein the above-mentioned members of the group D^{2b} may optionally be substituted by one or more substituents selected independently of one another from the group R^4 ,

5 or

D is selected from the group D^{3b} consisting of C_{1-6} -alkyl wherein the above-mentioned C_{1-6} -alkyl-group may optionally be substituted by one or more substituents selected independently of one another from the group R^5 ,

or

D is selected from the group D^{4b} consisting of phenyl

wherein the above-mentioned phenyl group may optionally be substituted by one or more substituents selected independently of one another from the group consisting of R^6 ,

or

D is selected from the group D^{5b} consisting of pyridyl wherein the above-mentioned pyridyl group may optionally be substituted by one or more substituents selected independently of one another from the group R^6 .

5

3. A compound according to claim 1 or 2, wherein

R^1 is selected independently for each R^1 from the group R^{1b} consisting of Hydrogen, fluorine, F_3C- , F_3C-CH_2- , C_{1-6} -alkyl-, C_{1-3} -alkynyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heterocyclyl-CO-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-, $(R^{10})_2N-$, $R^{10}O-CO-$, $(R^9)_2N-CO-$, $R^{10}-CO-(R^{10})N-$, $(R^9)_2N-CO-(R^{10})N-$, $(R^9)_2N-CO-O-$, and $R^{10}-O-CO-(R^{10})N-$,

where the above-mentioned, members F_3C-CH_2- , C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, heterocyclyl-CO-, and $R^{10}-O-C_{1-3}$ -alkyl-, may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, HO-, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-6} -alkyl-O-, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}$ -alkyl-, $(R^{10})_2N-CO-$, C_{3-6} -cycloalkyl-, C_{3-6} -cycloalkyl- C_{1-4} -alkyl- and C_{1-6} -alkyl-.

4. A compound according to any one or more of claims 1 to 3, wherein

R^2 is selected from the group R^{2b} consisting of

H-, fluorine, F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , C_{1-6} -alkyl-, $(R^{10})_2N-CO-$, $R^{10}-CO-(R^{10})N-$,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of

fluorine, chlorine, bromine, $NC-$, O_2N- , F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , $HO-C_{1-6}$ -alkyl-, C_{1-6} -alkyl- $O-C_{1-6}$ -alkyl-, C_{1-6} -alkyl-, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}$ -alkyl-, and $(R^{10})_2N-CO-$,

and in cases where D is a heterocyclyl group with NR^2 as ring member, R^2 shall be

independently of any other R^2 : H-, F_3C-CH_2- , HF_2C-CH_2- , C_{1-6} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-, heteroaryl, heteroaryl- C_{1-6} -alkyl-, $R^{10}-O-C_{1-3}$ -alkyl-, $R^{10}O-CO-$, $(R^{10})_2N-CO-$, $R^{10}-CO-$, and C_{1-6} -alkyl- SO_2- ,

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of

fluorine, $HO-$, $NC-$, O_2N- , F_3C- , HF_2C- , FH_2C- , F_3C-CH_2- , $HO-C_{1-6}$ -alkyl-, $R^{10}-O-C_{1-6}$ -alkyl-, C_{1-6} -alkyl-, $R^{10}-O-$, $(R^{10})_2N-$, $(R^{10})_2N-C_{1-3}$ -alkyl-, and $(R^{10})_2N-CO-$.

5. A compound according to any one or more of claims 1 to 4, wherein

R^3 is selected from the group R^{3b} consisting of
H-, hydroxy, C_{1-6} -alkyl- $O-$, whereby C_{1-6} -alkyl- $O-$ may optionally be substituted by one or more fluorine and/or one $HO-$.

6. A compound according to any one or more of claims 1 to 5, wherein

R^4 is selected from the group R^{4b} consisting of
 H-, fluorine, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl-, C_{2-6} -alkenyl-,
 C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl,
 aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-,
 $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $R^{10}O$ -CO-, $(R^{10})_2N$ -CO-, R^{10} -CO- $(R^{10})N$ -, R^{10} -
 CO-, $(R^{10})_2N$ -CO- $(R^{10})N$ - and R^{10} -O-CO- $(R^{10})N$ -,

where the above-mentioned members F_3C-CH_2 -, C_{1-6} -alkyl-, C_{2-6} -alkenyl-,
 C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -cycloalkyl- C_{1-6} -
 alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl, aryl- C_{1-6} -alkyl-,
 heteroaryl-, heteroaryl- C_{1-6} -alkyl-, R^{10} -O- C_{1-3} -alkyl- and $(R^{10})_2N$ - C_{1-3} -alkyl-,
 may optionally be substituted independently of one another by one or more
 substituents selected from the group consisting of fluorine, chlorine,
 bromine, NC-, O_2N -, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, HO - C_{1-6} -alkyl-, C_{1-6} -
 alkyl-O-, C_{1-6} -alkyl-O- C_{1-6} -alkyl-, C_{1-6} -alkyl-, $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-,
 and $(R^{10})_2N$ -CO-.

7. A compound according to any one or more of claims 1 to 6, wherein

R^5 is selected from the group R^{5b} consisting of
 H-, fluorine, NC-, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl-, C_{2-6} -alkenyl-,
 C_{2-6} -alkynyl-, C_{1-6} -alkyl-S-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -
 cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl,
 aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, R^{10} -O-, R^{10} -O- C_{1-3} -alkyl-,
 $(R^{10})_2N$ -, $(R^{10})_2N$ - C_{1-3} -alkyl-, $R^{10}O$ -CO-, $(R^{10})_2N$ -CO-, R^{10} -CO- $(R^{10})N$ -, R^{10} -
 CO-, $(R^{10})_2N$ -CO- $(R^{10})N$ -, and R^{10} -O-CO- $(R^{10})N$ -,

where the above-mentioned, members HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-6} -alkyl-,
 C_{2-6} -alkenyl-, C_{2-6} -alkynyl-, C_{1-6} -alkyl-S- C_{1-3} -alkyl-, C_{3-7} -cycloalkyl-, C_{3-7} -
 cycloalkyl- C_{1-6} -alkyl-, C_{3-7} -heterocyclyl-, C_{3-7} -heterocyclyl- C_{1-6} -alkyl-, aryl,
 aryl- C_{1-6} -alkyl-, heteroaryl-, heteroaryl- C_{1-6} -alkyl-, R^{10} -O- C_{1-3} -alkyl-, and
 $(R^{10})_2N$ - C_{1-3} -alkyl- may optionally be substituted independently of one

another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

8. A compound according to any one or more of claims 1 to 7, wherein

R⁶ is selected from the group R^{6b} consisting of H-, fluorine, chlorine, bromine, HO-, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, carboxy-, C₁₋₆-alkyl-, C₁₋₆-alkyl-S-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-, R¹⁰-O-C₁₋₃-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, R¹⁰O-CO-, (R¹⁰)₂N-CO-, R¹⁰-CO-(R¹⁰)N-, R¹⁰-CO-, (R¹⁰)₂N-CO-(R¹⁰)N-, and R¹⁰-O-CO-(R¹⁰)N-,

where the above-mentioned, members HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₆-alkyl-, C₁₋₆-alkyl-S-C₁₋₃-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₆-alkyl C₃₋₇-heterocyclyl-, C₃₋₇-heterocyclyl-C₁₋₆-alkyl-, aryl, aryl-C₁₋₆-alkyl-, heteroaryl-, heteroaryl-C₁₋₆-alkyl-, R¹⁰-O-C₁₋₃-alkyl- and (R¹⁰)₂N-C₁₋₃-alkyl-, may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, NC-, O₂N-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, HO-C₁₋₆-alkyl-, C₁₋₆-alkyl-O-, C₁₋₆-alkyl-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, (R¹⁰)₂N-, (R¹⁰)₂N-C₁₋₃-alkyl-, and (R¹⁰)₂N-CO-,

9. A compound according to any one or more of claims 1 to 8, wherein

R⁹ is selected independently for each R⁹ from the group R^{9b} consisting of H-, C₁₋₆-alkyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, and heteroaryl-C₁₋₃-alkyl-, where the above-mentioned members C₁₋₆-alkyl-, C₂₋₆-alkinyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, aryl, aryl-C₁₋₃-alkyl-, heteroaryl, and heteroaryl-C₁₋₃-alkyl- may optionally be substituted independently of one

another by one or more substituents selected independently from one another from the group consisting of fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-O- and C₁₋₆-alkyl-.

10. A compound according to any one or more of claims 1 to 9, wherein

R¹⁰ is selected independently for each R¹⁰ from the group R^{10b} consisting of H- (but not in case is part of a group being selected from R¹⁰O-CO-, R¹⁰-SO₂- or R¹⁰-CO-), C₁₋₆-alkyl-, C₃₋₇-cycloalkyl-, C₃₋₇-cycloalkyl-C₁₋₃-alkyl-, aryl and heteroaryl,

and in case where two R¹⁰ groups both are bound to the same nitrogen atom they may together with said nitrogen atom form a 3 to 12 membered heterocyclyl ring, and wherein one of the -CH₂-groups of the heterocyclic ring formed may be replaced by -O-, -NH-, -N(C₃₋₆-cycloalkyl)-, -N(C₃₋₆-cycloalkyl-C₁₋₄-alkyl)- or -N(C₁₋₄-alkyl)- and

where the above-mentioned members may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, NC-, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, CH₃-O-C₁₋₆-alkyl-, C₁₋₆-alkyl-, and C₁₋₆-alkyl-O-.

11. A compound according to claim 1, wherein

D is selected from the group consisting of cyclopentyl, cyclohexyl, 3-pentyl-, phenyl, tetrahydropyranyl, tetrahydrofuranyl and pyridyl, wherein the above-mentioned cyclopentyl, cyclohexyl, 3-pentyl-, phenyl, and pyridyl groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine

or methyl and

wherein the above-mentioned tetrahydropyranyl and tetrahydrofuranyl groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of methyl.

L is selected from the integers 0, 1 and 2,


x is selected from the integers 0, 1, 2 and 3 ,

y is 0,

5

and

R¹ is selected independently for each R¹ from the group R^{1d} consisting of C₁₋₃-alkyl-, C₁₋₃-alkyl-O-CO-, HO-CO-, (C₁₋₆-alkyl)₂N-CO-, oxadiazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, thienyl, pyrrolyl, furanyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, oxadiazolyl-C₁₋₃-alkyl-, oxazolyl-C₁₋₃-alkyl-, isoxazolyl-C₁₋₃-alkyl-, triazolyl-C₁₋₃-alkyl-, thiazolyl-C₁₋₃-alkyl-, pyrrolyl-C₁₋₃-alkyl-, furanyl-C₁₋₃-alkyl-, pyrazolyl-C₁₋₃-alkyl-, pyridyl-C₁₋₃-alkyl-, pyridazinyl-C₁₋₃-alkyl-, pyrimidinyl-C₁₋₃-alkyl-, pyrazolyl-C₁₋₃-alkyl-,



where the above-mentioned, members may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F₃C-, HF₂C-, FH₂C-, F₃C-CH₂-, C₁₋₃-alkyl-O- and C₁₋₃-alkyl-.

12. A compound according to claim 1, wherein

D is selected from the group consisting of cyclopentyl, cyclohexyl, 3-pentyl-,

phenyl and pyridyl,

wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine or methyl.

L is 1,


x is selected from the integers 1 and 2,

y is 0,

5

and

R^1 is selected independently for each R^{1e} from the group consisting of C_{1-3} -alkyl-, $(C_{1-6}$ -alkyl) $_2$ N-CO-, oxadiazolyl, pyrazolyl-methyl-,



where the above-mentioned, members may optionally be substituted independently of one another by one or more substituents selected independently of one another from the group consisting of fluorine, F_3C -, HF_2C -, FH_2C -, F_3C-CH_2 -, C_{1-3} -alkyl-O- and C_{1-3} -alkyl-.







13. A compound according to any one or more of claims 1 to 12, wherein











D is selected from the group consisting of cyclopentyl, cyclohexyl and pyridyl, wherein the above-mentioned groups may optionally be substituted by one or more substituents selected independently of one another from the group consisting of fluorine, chlorine or methyl.










10 14. A compound according to any one or more of claims 1 to 13 with the provision that











if **D** is oxetanyl, which is bound via the carbon atom next to the oxygen of the oxetanyl, there is no substituent attached to said carbon atom via an integral -CH₂- group.











- 5 15. A compound according to claim 1, wherein the compound is selected from the group of



No.	Compound	No.	Compound
1		2	
3		4	
5		6	

7		8	
9		10	
11		12	
13		14	
15		16	

17		18	
19		20	
21		22	
23			
24		25	

26		27	
28		29	
30		31	
32		33	
34		35	

36		37	
38		39	
40		41	
42		43	
44		45	

46		47	
----	---	----	---

and salts thereof, preferably pharmaceutically acceptable salts thereof.

16. Use of a compound according to any one of claims 1 to 15 as a medicament for humans.

17. Use of a compound according to any one of claims 1 to 15 as a medicament, preferably as a medicament for the treatment of a CNS disease, more preferably as a medicament for the treatment of a CNS disease, the treatment of which is accessible by the inhibition of PDE9.

18. Use of a compound according to any one of claims 1 to 15 for the manufacture of a medicament for the treatment of a disease that is accessible by the inhibition of PDE9.

19. Use of a compound according to any one of claims 1 to 15 for the manufacture of medicament for the treatment, amelioration or prevention of a disease or condition selected from the group of cognitive impairment being related to perception, concentration, cognition, learning and memory.

20. Use according to claim 19, characterised in that the medicament is for the treatment, amelioration or prevention of a disease or condition selected from the group of cognitive impairment being related to age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic dementia, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome,

Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia and Korsakoff's psychosis.

5 21. Use of a compound according to any one of claims 1 to 15 for the manufacture of medicament for the treatment of Alzheimer's disease.

22. Use of a compound according to any one of claims 1 to 15 for the manufacture of medicament for the treatment of cognitive impairment which is due to Alzheimer's disease.

10 23. Use of a compound according to any one of claims 1 to 15 for the manufacture of medicament for the treatment of a disease or condition selected from the group of sleep disorders, bipolar disorder, metabolic syndrome, obesity, diabetes mellitus, hyperglycemia, dyslipidemia, impaired glucose tolerance, and a disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus and spleen.

15 24. A compound according to any of claims 1 to 15 for use in the treatment of a disease or condition as defined in any one of claims 17 to 23.

25. Pharmaceutical composition comprising a compound according to any one or more of claims 1 to 15 and a pharmaceutical carrier.

20 26. Method for the treatment of a condition as defined in any one of claims 17 to 23 in a patient comprising administering to said patient a therapeutically active amount of a compound according to any one or more of claims 1 to 185.

27. Combination of a compound according to any one or more of claims 1 to 15 with another active agent, for example another active agent for the treatment of Alzheimer's disease.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2010/061735

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D487/04 A61K31/522 A61P25/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/093269 A2 (BAYER CROPSOURCE AG [DE]; LINKER KARL-HEINZ [DE]; ANDREE ROLAND [DE];) 13 November 2003 (2003-11-13) examples 5,47,53,63,73,92,101,106	1
X	US 3 732 225 A (BREUER H ET AL) 8 May 1973 (1973-05-08) * abstract; example 11	1
X	DATABASE CHEMCATS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002556399 retrieved from STN Database accession no. ALB-H01677136, F2135-0885 * abstract	1
	-/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

15 September 2010

Date of mailing of the international search report

24/09/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, Paola

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2010/061735

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& 6 July 2007 (2007-07-06), "AMBINTER STOCK SCREENING COLLECTION", AMBINTER, 50, AVENUE DE VERSAILLES, PARIS, F-75016, FRANCE -----	
Y	WO 2004/099211 A1 (BAYER HEALTHCARE AG [DE]; HENDRIX MARTIN [DE]; BAERFACKER LARS [DE]; E) 18 November 2004 (2004-11-18) cited in the application the whole document -----	1-27
Y	DE 102 38 722 A1 (BAYER AG [DE]) 11 March 2004 (2004-03-11) cited in the application the whole document -----	1-27
A	JAY A MARKWALDER ET AL: "Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo [3,4-d]pyrimidin-4-one Inhibitors of Cyclin-dependent Kinases" JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, 27 October 2004 (2004-10-27), pages 5894-5911, XP002399637 AMERICAN CHEMICAL SOCIETY, WASHINGTON, US ISSN: 0022-2623 table 5 -----	1-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/061735

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03093269	A2	13-11-2003	AU	2003224111 A1		17-11-2003
			BR	0309873 A		26-04-2005
			CA	2484997 A1		13-11-2003
			DE	10219435 A1		13-11-2003
			EP	1504005 A2		09-02-2005
			JP	2005531549 T		20-10-2005
			US	2005209251 A1		22-09-2005
<hr/>						
US 3732225	A	08-05-1973	DE	2136950 A1		17-02-1972
			FR	2100945 A1		24-03-1972
<hr/>						
WO 2004099211	A1	18-11-2004	AU	2004235915 A1		18-11-2004
			CA	2524900 A1		18-11-2004
			EP	1626971 A1		22-02-2006
			JP	2006525966 T		16-11-2006
			UY	28312 A1		31-12-2004
<hr/>						
DE 10238722	A1	11-03-2004	AU	2003258597 A1		08-04-2004
			CA	2496292 A1		01-04-2004
			WO	2004026286 A2		01-04-2004
			EP	1534285 A2		01-06-2005
			JP	2006501272 T		12-01-2006
			US	2006100222 A1		11-05-2006
			US	2010210839 A1		19-08-2010
<hr/>						